Pyrazole compounds as cullin ring ubiquitin ligase compounds

Abstract

The present invention relates to compounds with the ability to modulate / stimulate / induce, particularly induce degradation of a target protein / target proteins. Such target protein / target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and / or neurological disorder. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds.

Description

[0001] PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to compounds with the ability to modulate / stimulate / induce, particularly induce ubiquitination of a target protein. The compounds of the present invention may stimulate / induce degradation of a target protein via ubiquitination of a target protein by the cullin-RING ubiquitin ligase (CRL). Such target protein may be a protein involved in a disease, like cancer, metabolic disorder, infectious disease and / or neurological disorder. The invention also relates to the compound and a composition comprising the compound for use as a medicament as well as a pharmaceutical composition comprising the compound. Particularly, the compound of the present invention may facilitate degradation of a protein associated with cancer, metabolic disorder, infectious disease and / or neurological disorder. Furthermore, the present invention relates the compound for use as a medicament, such as for use in treating cancer, metabolic disorder, infectious disease and / or neurological disorder and to a method for treating a disease, such as cancer, metabolic disorder, infectious disease and / or neurological disorder, comprising administering the compound of the present invention.

[0004] BACKGROUND OF THE INVENTION

[0005] Protein degradation plays a central role in many cellular functions such as for cell maintenance and normal function. Accordingly, degradation of proteins, such as proteins which are associated with cellular functions, e.g., maintenance function, has implications for the cell's proliferation, differentiation, and death. In this context, the induction of targeted protein degradation (TPD) by compounds, thereby reducing the activity of a protein by removing the target protein, is a highly promising paradigm in drug discovery compared to inhibitors of proteins which would reduce the activity of a protein by simply blocking the activity of said protein. Utilizing a cell's protein degradation pathway can, therefore, provide means for reducing or removing protein activity.

[0006] Until recently, small molecules that induce protein destabilization typically emerged serendipitously. Examples for this are the estrogen receptor (ER) modulator Fulvestrant, or the CRL4CRBNmodulators thalidomide and related compounds such as lenalidomide or pomalidomide (collectively referred to as “IMiDs” and also known in the art as "molecular glue"). All these cases represent approved drugs, which clinically validates the concept of TPD as a therapeutic reality. Lenalidomide was, in fact, with total revenues of $9.7 billion, one of the commercially most successful drugs of 2018.

[0007] Noteworthy, it took several decades of research to decipher the molecular mechanism of IMiDs as small molecule degraders. Rational strategies to generalize the concept of TPD were described by Winter et al. (Winter, G. E.*, Buckley, D. L.*, Paulk, J., Roberts, J., Souza, A., De-Phagano, S., and Bradner, J. E. (2015) Phthalimide Conjugation as a Strategy for in i / fi / o Target Protein Degradation. Science 348, 1376-81), describing the formation of heterobifunctional molecules by conjugating IMiD-like chemical structures to known targeting ligands via flexible linkers. These heterobifunctional small molecules (often also called “degraders”) are shown to function via binding to a protein of interest (via the interchangeable targeting ligand) and the E3 ligase CRL4CRBN, i.e. via the IMiD-like chemical agent. Thereby, binding induces molecular proximity between the target protein and the E3 ligase, prompting ubiquitination and proteolytic degradation of the former. Particularly, the ubiquitin conjugation on target proteins is mediated by an enzymatic cascade comprised by an El ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase that attach ubiquitin to the target protein (Hershko et al., Nat. Med. 6, 1073-1081 (2000); Komander et al., Annu. Rev. Biochem. 81, 203-229 (2012)).

[0008] Thus, the ubiquitin-proteasome pathway, one of the cell's major degradation pathways, which is a critical pathway that regulates key regulator proteins and degrades misfolded and abnormal proteins, is found to be a valuable tool, in particular in therapeutic applications, for degrading target proteins by covalent attachment of ubiquitin to the said target protein.

[0009] The development of heterobifunctional degraders (PROTAC) that have the ability to hijack the CRBN ligase complex is associated with certain caveats. For example, only certain E3 ligases can be harnessed by such heterobifunctional degraders. Thereby, ligands typically bind to CRBN, VHL, clAlP or MDM2. Furthermore, a part of the heterobifunctional degrader structure of PROTACs is a ligand to the target protein, thereby precluding the application of the technology to “unligandable” proteins (see, e.g., Surade and Blundell (2012); Chemistry & Biology, Volume 19, Issue 1, pp.42-50). Sometimes, the high molecule weight of the resulting heterobifunctional degraders may impact pharmacology and bioavailability.

[0010] There is a need for efficient small molecules that are able to bind to E3 ligase components, and which are thus suitable to be to degrade desired target proteins.

[0011] Small molecules may modulate E3 ligases and other components of the ubiquitin - proteasome pathway also by operating via a “molecular glue” type of mechanism. By this means, such compounds may not rely on the availability of an accessible, hydrophobic binding pocket. For example, IMiDs can induce cooperative associations with target proteins that are naturally not bound by CRBN, i.e. without requiring an additional linkage with a targeting-moiety. This in turn prompts ubiquitination and proteasomal degradation of bound target proteins such as the transcription factors IKZF1 and IKZF3. As another example, aryl sulfonamides can re-direct the activity of the E3 ligase DCAF15 to degrade the splicing factor RBM39 in an analogous manner as IMiDs. Similarly, the phytohormone auxin is known to re-direct the target space of the E3 ligase Tirl to induce degradation of the Aux / IAA transcriptional repressors.

[0012] Until now, targeting proteins which are devoid of a hydrophobic binding pocket or a binding site that leads to inactivation of said target proteins are beyond the reach of commonly used compounds which may be developed for therapeutic uses. In other words, this approach does not allow degradation of target proteins, such as target proteins without an accessible hydrophobic pocket or inhibitory binding site. In this regard, compelling disease-relevant targets such as MYC, RAS, or b-catenin, remain beyond the reach of therapeutic development.

[0013] Thus, novel paradigms in drug design are highly needed. Hence, in view of the above, the technical problem underlying the present invention is the provision of compounds that are able to induce ubiquitination of a target protein, in particular a target protein desired to be degraded in a cell, like a cell implicated in or associated with a disease. In particular, it is an object of the present invention to provide compounds with a high potency of inducing degradation of a target protein, in particular a target protein desired to be degraded in a cell, like a cell implicated in or associated with a disease.

[0014] The solution to this technical problem is provided by the embodiments as defined herein below and as characterized in the claims.

[0015] SUMMARY OF THE INVENTION

[0016] The invention relates to the compounds as described herein, in particular to compounds of formula (I), as well as to pharmaceutical compositions comprising the same, and their use in the treatment of various diseases which can be treated by targeted degradation of certain proteins, namely in particular cyclin K (CONK) and / or CDK12 and / or CDK13.

[0017] The compounds as disclosed herein and in context of the invention are capable of modulating / stimulating / inducing degradation of a target protein, in particular via ubiquitination of a target protein by the cu I lin- RING ubiquitin ligase (CRL). In the context of the invention, the compound has the capacity of modulating / stimulating / inducing, particularly inducing ubiquitination of a target protein by enhancing the cullin-RING ubiquitin ligase activity / CRL activity.

[0018] The compounds as disclosed herein and in the context of the invention may particularly be used as molecular glues as described herein and illustrated in the appended Examples.

[0019] Molecular glues are capable of degrading target protein(s) by orchestrating direct interactions between target and cullin-RING ligases (CRLs). Molecular glues have the potential to induce the elimination of disease-relevant proteins otherwise considered “undruggable”. The mechanism of action by molecular glues can be exemplified by the clinically approved molecular glues / degraders of thalidomide analogs (I MiDs) . Binding of I Mi Ds to the CRL4CRBNE3 ligase causes recruitment of selected zinc finger transcription factors (TFs), leading to their ubiquitination and subsequent proteasomal degradation (Lu, G. et al. Science3%3, 305-309, doi:10.1126 / science.1244917 (2014); Kronke, J. eta / . Science3%3, 301-305, doi:10.1126 / science.1244851 (2014); Sievers, Q. L. et a! Science 362, doi:10.1126 / science.aat0572 (2018); Gandhi, A. K. et a / . British Journal of haematology 164, 811-821, doi:10.1111 / bjh.12708 (2014)).

[0020] Noteworthy, I MiDs have per se no measurable binding affinity to the degraded TFs. However, they orchestrate molecular recognition between ligase and TF by inducing several protein-protein interactions proximal to the binding interface. Certain aryl sulfonamides around the clinically tested compound indisulam act as molecular glues between the CRL4DCAF15ligase and the splicing factor RBM39, causing the targeted degradation of the latter (Han, T. et ai.. Science, doi:10.1126 / science.aal3755 (2017); Uehara, T. et ai. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat Chem Bio / 13, 675-680, doi:10.1038 / nchembio.2363 (2017); Bussiere, D. E. et ai. Nat Chem Bio / 16, 15-23, doi:10.1038 / s41589-019-0411-6 (2020); Ting, T. C. et ai. Cell reports 29, 1499-1510.el496, doi:10.1016 / j.celrep.2019.09.079 (2019); Faust, T. B. et ai. Nat Chem Biol 16, 7 -14, doi:10.1038 / s41589-019-0378-3 (2020); Du, X. et ai. Structure (London, England : 1993) 27 , 1625-1633. el623, doi:10.1016 / j.str.2019.10.005 (2019).)

[0021] The molecular glue mechanism of action therefore enables the destabilization of target proteins otherwise considered "unligandable" and thus outside the reach of both traditional small-molecule inhibitors and also of heterobifunctional degraders. The compounds of the invention are able to induce the destabilization of disease associated target proteins, in particular cyclin K (CCNK) and / or CDK12 and / or CDK13. The compounds of the invention act, inter alia, as CCNK degraders. As described herein and illustrated in the appended Examples, the compounds of the invention are able to degrade target protein(s), in particular cyclin K (CCNK) and / or CDK12 and / or CDK13, independent of a dedicated substrate receptor, which functionally differentiates this mechanism from previously characterized degraders.

[0022] In this context, CDK12, CDK13 and / or CCNK may be desired or desirable to be degraded in an in vivo or in vitro situation, for example in a cell implicated in or associated with a disease, like a cancer cell, where CDK12, CDK13 and / or CCNK should be degraded. Thus, the target protein(s) as disclosed herein and in the context of the invention may be target protein(s) associated with cancer, wherein the one or more protein(s) associated with cancer are in particular selected from the group consisting of CDK12, CDK13 and CCNK.

[0023] An option of the "induction of ubiquitination of a target protein" may comprise the conformational change of the target protein that has been induced as a direct consequence of binding / interaction with said compound inducing the ubiquitination of the target protein. For example, binding of a compound as described herein to a target protein may lead to a conformational change of said protein and thereby stabilize an interaction of one or more target protein(s) with one or more component(s) of the E3 ligase complex that results in ubiquitination and degradation of said one or more target protein(s). Particularly, a compound binding to CDK12 / 13:CCNK prompts interaction with a DDB1:CUL4B E3 ligase complex, leading to the ubiquitination and degradation of CCNK. By this means, a target protein as described herein and illustrated in the appended examples, such as CCNK, may be degraded via a direct or an indirect binding mechanism of a compound as described herein, such as by binding of said compound to a protein associated with a target protein. A compound may bind to CDK12 / 13, which is associated with CCNK, thereby leading to the ubiquitination and degradation of CCNK. This interaction is independent from a particular substrate receptor of an E3 ligase. Thus, a compound as described herein and in context of the invention can degrade one or more target protein(s) via an E3 ligase independent of a particular substrate receptor of said E3 ligase.

[0024] In particular, the compounds of the present invention may bind to the active site of CDK12 / 13, thereby prompting a change in structural conformation, which promotes the binding of CDK12:CCNK and CDK13:CCNK, respectively, to DDB1:CUL4B. As such, CDK12 and CDK13 basically serve to present CCNK to the ligase, leading to the degradation of, among others, CCNK, followed by a potentially slightly weaker degradation of CDK12 and CDK13.

[0025] Thus, it has been surprisingly found that the compounds of the present invention are able to induce degradation of the target protein, which is in particular cyclin K (CCNK) and / or CDK12 and / or CDK13. It has also been found that in certain embodiments, the compounds of formula (I) achieve advantageous degradation kinetics of the target protein / target proteins, in particular of CCNK.

[0026] In one aspect, the present invention relates to compounds of the following formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof: 5 wherein A is a 5-membered heteroaryl group, which comprises one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heteroaryl group is independently unsubstituted or substituted with one or more, same or different substituents RA, provided that at least one substituent RAis present at the heteroaryl group A; wherein RAis halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl- C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1- C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl B is any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB1is H; RB2is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB3is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB4is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H; X1is N or CRB6; Y1is N or CRB7; Z1is N or CRB8; provided that one, but not more than one of X1, Y1, and Z1is N; RB6is H; RB7is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB8is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB9is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB10is H; RB11is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB12is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB13is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB14is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB15is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB16is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB17is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RNis C1-C4-alkyl; and R1is H or C1-C4-alkyl; and wherein the compound is not any one of or a tautomer thereof. In a preferred embodiment, RB1is H; RB2is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB3is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB4is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H; RB6is H; RB7is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB8is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB9is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB10is H; RB11is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB12is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB13is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB14is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB15is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB16is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB17is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1- C4-alkyl-S-, C1-C4-alkyl- alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl. In another preferred embodiment, A is the following heteroaryl group wherein X2is N or NH; Y2is CH, CRA2, N, NH, or S; Z2is CH, CRA4, N, NH, or S; provided that at least one of Y2and Z2is different from CH, CRA2or CRA4; and wherein the wavy line marks the connection to the remainder of the molecule; and wherein the dashed lines within the 5-membered ring indicate the presence of double bonds, such that an aromatic ring system is formed; and wherein RA2, RA3, and RA4represent the one or more, same or different substituents RAat the heteroaryl group A as defined above for formula (I). In another preferred embodiment, A is any one of the following heteroaryl groups: ; wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2- alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2- alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl. In another preferred embodiment, A is any one of the following heteroaryl groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl. In another preferred embodiment, ; wherein the wavy line marks the connection to the remainder of the molecule; and wherein RA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl. In another preferred embodiment, RA3is any one of the following groups CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, wherein the wavy line in each case marks the connection to the A group. In another preferred embodiment, RA3is , wherein the wavy line marks the connection to the A group. In another preferred embodiment, B is wherein the wavy line marks the connection to the remainder of the molecule; and wherein RB1is H; RB2is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB3is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB4is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H. In another preferred embodiment, B wherein the wavy line marks the connection to the remainder of the molecule; and wherein RB7is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB8is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB9is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; and RB10is H. In another preferred embodiment, R1is H In another preferred embodiment, R1is C1-C4-alkyl. In another preferred embodiment, the compound is a compound of formula (IA) In another preferred embodiment, the compound is a compound of formula (IB) In another preferred embodiment, R1is CH3. In another preferred embodiment, the compound is selected from the group consisting of: N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(3-(hydroxymethyl)phenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(3-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropylthiazol-2-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, and N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide. In a further aspect, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound of formula (I) as defined herein, and optionally a pharmaceutically acceptable carrier, diluent or excipient. In yet another aspect, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in medicine. In particular, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in treating or preventing cancer, a metabolic disorder, a neurologic disorder or an infectious disease. In a preferred embodiment, the present invention relates to a compound of formula (I) as defined herein or a pharmaceutical composition comprising the same as defined herein for use in treating or preventing cancer. In one embodiment, the cancer is a solid tumor cancer. In another embodiment, the cancer is selected from the group consisting of leukemia, particularly acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), and a chronic leukemia including chronic myeloid leukemia; lymphoma, particularly Non-Hodgkin Lymphoma and Hodgkin Lymphoma; head and neck cancer; esophageal cancer; adenoid cystic carcinoma; osteosarcoma; ovarian cancer; Ewing’s sarcoma; lung cancer; neuroblastoma; gastrointestinal cancer; endometrial cancer; cervical cancer; medulloblastoma; prostate cancer; breast cancer; thyroid cancer; meningioma; liver cancer; colorectal cancer; pancreatic cancer; chondrosarcoma; osteosarcoma; and kidney cancer. In a preferred embodiment, the cancer is selected from the group consisting of lymphoma, liver cancer, breast cancer, neuroblastoma, cervical cancer, Ewing’s sarcoma, and lung cancer, in particular MYCL-overexpressing lung cancer. In a more preferred embodiment, the cancer is selected from liver cancer, particularly hepatocellular carcinoma; breast cancer, particularly HER2-overexpressing breast cancer or triple-negative breast cancer; and neuroblastoma, particularly MYCN-overexpressing neuroblastoma. In another preferred embodiment, the cancer is a cancer in which HER2 overexpression is accompanied by CDK12 overexpression. DETAILED DESCRIPTION OF THE INVENTION The compounds of formula (I) as described herein and illustrated in the appended examples degrade one or more target protein(s), in particular CCNK, CD12 and / or CDK13, most likely via interaction with a component of the cullin RING E3 ligase present in several family members of the cullin RING E3 ligase. Particularly, the family members of the cullin RING E3 ligase can be diversified, e.g., by their respective substrate receptors, such as CRBN or DCAF15. The compounds of formula (I) as described herein can bind to components of the cullin RING E3 ligase family other than the substrate receptor, and thus these compounds may degrade one or more target protein(s) independent from the substrate receptor. Thus, the ability of molecular glues to degrade one or more target protein(s) via interaction with a cullin RING E3 ligase may not be limited to a particular family member of a cullin RING E3 ligase. A compound of formula (I) as described herein degrades one or more target protein(s) associated with cancer, in particular CDK12, CDK13 and / or cyclin K (CCNK). The mechanism of action by a compound of formula (I), which may be described as “molecular glue”, resulting in degradation of one or more target protein(s), in particular CDK12, CDK13 and / or cyclin K (CCNK), seems to rely on the ability of molecular glues to orchestrate protein-protein interactions between a cullin RING E3 ligase and one or more target protein(s) to be degraded. As described herein, this can be achieved by stabilizing an interaction of CDK12 and / or CDK13 bound to CCNK with the cullin RING E3 ligase, particularly one or more components of the cullin RING E3 ligase such as CUL4B and / or DDB1. In the following, preferred embodiments of the substituents in the compounds of the above formula (I) are described in further detail. It is to be understood that each preferred embodiment is relevant on its own as well as in combination with other preferred embodiments. Furthermore, it is to be understood that the preferences in each case also apply to the stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates of the compounds of the invention. As indicated above, the compounds of the present invention are compounds of formula (I): With regard to ring A in the compounds of formula (I) and the substituents RAthereon, the following preferred embodiments are relevant. As indicated above, in the compounds of formula (I), A is a 5-membered heteroaryl group, which comprises one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heteroaryl group is independently unsubstituted or substituted with one or more, same or different substituents RA, provided that at least one substituent RAis present at the heteroaryl group A; wherein RAis halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl- C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1- C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl. In a preferred embodiment, A is a 5-membered heteroaryl group, which comprises one or more, preferably one, two, or three, more preferably two or three, even more preferably two, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein the heteroaryl group is substituted with one or more, preferably one or two, more preferably one, same or different substituents RA. In a more preferred embodiment, A is a 5-membered heteroaryl group selected from the group consisting of imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, isothiazolyl, and thiazolyl, preferably pyrazolyl, oxazolyl, and thiazolyl, more preferably pyrazolyl and thiazolyl, wherein the aforementioned heteroaryl groups are independently substituted with one or more, preferably one or two, more preferably one, same or different substituents RA. If A is isothiazolyl, it is preferred that RAis not CH3. In another more preferred embodiment, A is a 5-membered heteroaryl group selected from the group consisting of imidazolyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, and thiazolyl, preferably pyrazolyl, oxazolyl, and thiazolyl, more preferably pyrazolyl and thiazolyl, wherein the aforementioned heteroaryl groups are independently substituted with one or more, preferably one or two, more preferably one, same or different substituents RA. In a particularly preferred embodiment, A is pyrazolyl, wherein the pyrazolyl is substituted with one or more, preferably one or two, more preferably one, same or different substituents RA. In another particularly preferred embodiment, A is thiazolyl, wherein the thiazolyl is substituted with one or more, preferably one or two, more preferably one, same or different substituents RA. Further, it is preferred that the heteroaryl group A is attached to the amide moiety of the remainder of the molecule via a carbon atom. Further, it is preferred that the heteroaryl group A comprises more than one heteroatom, preferably two or three heteroatoms, particularly preferably two heteroatoms. Accordingly, in a preferred embodiment, A is the following heteroaryl group A* ; wherein X2is N or NH; Y2is CH, CRA2, N, NH, O, or S; Z2is CH, CRA4, N, NH, O, or S; provided that at least one of Y2and Z2is different from CH, CRA2or CRA4; and wherein the wavy line marks the connection to the remainder of the molecule; and wherein the dashed lines within the 5-membered ring indicate the presence of double bonds, such that an aromatic ring system is formed; and wherein RA2, RA3, and RA4represent the one or more, same or different substituents RAat the heteroaryl group A as defined for the compound of formula (I); so that RA2, RA3, and RA4are each independently selected from the group consisting of halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2- alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, and heterobicyclyl-C1-C2- alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl. In the context of said heteroaryl group A*, preferably, X2is N or NH; Y2is CH, CRA2, N, NH, or S; Z2is CH, CRA4, N, NH, or S; more preferably, X2is N or NH; Y2is CH, CRA2, N, or NH; Z2is CH, CRA4, N, NH, or S; even more preferably, X2is N or NH; Y2is CH, CRA2, N, or NH; Z2is CH, CRA4, or S; even more preferably, X2is N or NH; Y2is N or NH; Z2is CH or CRA4, preferably CH; or X2is N; Y2is CH or CRA2, preferably CH; Z2is S, particularly preferably, X2is N or NH; Y2is N or NH; Z2is CH or CRA4, preferably CH. As indicated above, in a particularly preferred embodiment, the heteroaryl group A comprises two heteroatoms. Accordingly, in the heteroaryl group A*, it is particularly preferred that one of Y2and Z2is different from CH, CRA2or CRA4and one of Y2and Z2is CH, CRA2or CRA4, preferably CH. Further, it is to be understood that whether a nitrogen atom in the heteroaryl group A or A* is N or NH results from the aromatic ring system in the heteroaryl group A or A* and the possible tautomers formed thereby. In particular, the skilled person is aware that if only one of X2, Y2, and Z2in the heteroaryl group A* is a nitrogen atom and the remaining heteroatom(s) are O or S, then said one nitrogen atom is present as N. If more than one of X2, Y2, and Z2in the heteroaryl group A* is a nitrogen atom, then one of said nitrogen atoms is present as NH and the remaining one(s) as N. Accordingly, in the heteroaryl group A*, at most one of X2, Y2, and Z2is NH. Further, if more than one nitrogen atom is present in the heteroaryl group A or A* (e.g. pyrazolyl), two different tautomers are formed, which will typically be present in chemical equilibrium in solution with the thermodynamically more stable tautomer being present in an excess and the two tautomers readily interconverting. Therefore, whenever only one of the two possible tautomers of the heteroaryl group A or A* (e.g. in the case of pyrazolyl) of the compound of formula (I) is depicted, it is intended to be referred to the other tautomer as well. For illustration, the two possible tautomers for the heteroaryl group A or A* in the case of pyrazolyl are shown below: . Thus, when the heteroaryl group A or A* of the compound of formula (I) is depicted herein as only one tautomeric form (e.g. as A1-T1 or A1-T2), it is also referred to the heteroaryl group A or A* of the compound of formula (I) in the respective other tautomeric form, as well as mixtures thereof. Further, when for clarity reasons the heteroaryl group A or A* of the compound of formula (I) is depicted herein in the different tautomeric forms (e.g. as A1- T1 and A1-T2), it is also referred to mixtures thereof. Similarly, if the compounds of formula (I) are depicted herein comprising one tautomeric form of the heteroaryl group A or A* (e.g. compounds of formula (Ia-T1) or (IA-T2)), it is also referred to the compounds of formula (I) comprising the respective other tautomeric form of the heteroaryl group A or A*, as well as mixtures thereof. If compounds of formula (I) with different tautomeric forms of the heteroaryl group A or A* are depicted herein (e.g. compounds of formula (Ia-T1) and (IA-T2)), it is also referred to mixtures thereof. In view of the above, in a preferred embodiment, A is any one of the following heteroaryl groups: wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RA2, RA3, and RA4represent the one or more, same or different substituents RAat the heteroaryl group A as defined for the compound of formula (I); so that RA2, RA3, and RA4are each independently selected from the group consisting of halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2- alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, and heterobicyclyl-C1-C2- alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably wherein RA2, if present, is C1-C2-alkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl; RA4, if present, is halogen, CN, C1-C2-alkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl; and RA3is halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl- C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, and heterobicyclyl- C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl. In a particularly preferred embodiment, RA3is the only substituent RAat the heteroaryl group A or A* of the compounds of formula (I). Accordingly, in a more preferred embodiment, A wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In an even more preferred embodiment, A is any one of the following heteroaryl groups: wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In an even more preferred embodiment, A is any one of the following heteroaryl groups: wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In an even more preferred embodiment, ;wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In another even more preferred embodiment, ; wherein the wavy line marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In one particularly preferred embodiment, A i wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In another particularly preferred embodiment, wherein the wavy line in each case marks the connection to the remainder of the molecule and wherein RA3is as defined above or in the preferred embodiments defined below. In a preferred embodiment, the compound of formula (I) is thus a compound of formula (Ia-

[0027] In another embodiment, the compound of formula (I) is a compound of formula (Ib): Particularly preferred compounds of formula (I) are compounds of formula (Ia-T1) or its tautomer (Ia-T2). In one particularly preferred embodiment, the compound of formula (I) is a compound of formula (Ia-T1). In another particularly preferred embodiment, the compound of formula (I) is a compound of formula (Ia-T2). In connection with the compounds of formula (I), in particular the compounds of formula (Ia-T1), (Ia-T2), and (Ib), as well as in connection with the preferred embodiments regarding the heteroaryl group A or A* defined above, in particular (A1-T1), (A1-T2), (A2- T1), (A2-T2), (A3), (A4), (A5), (A6), (A7), (A8), (A9), or (A10), preferably (A1-T1), (A1-T2), (A5), (A6), (A9), or (A10), more preferably (A1-T1), (A1-T2), or (A10), particularly preferably (A1-T1) or (A1-T2), the following preferences regarding the substituents RA, RA2, RA3, and RA4, if present, are relevant. As indicated above, at least one substituent RAis present at the heteroaryl group A of the compounds of formula (I). In a preferred embodiment, the heteroaryl group A is substituted with one, two, or three substituents RA, wherein preferably each substituent RAis attached at a carbon atom of the heteroaryl group A In a more preferred embodiment, the heteroaryl group A is substituted with one or two substituents RA, wherein preferably each substituent RAis attached at a carbon atom of the heteroaryl group A. In an even more preferred embodiment, the heteroaryl group A is substituted with only one substituent RA, wherein preferably the substituent RAis attached at a carbon atom of the heteroaryl group A. In another preferred embodiment, the heteroaryl group A is at least substituted with a substituent RArepresented by substituent RA3. In a more preferred embodiment, the heteroaryl group A is substituted with a substituent RArepresented by RA3and two further substituents RArepresented by RA2and RA4, more preferably the heteroaryl group A is substituted with a substituent RArepresented by RA3and one further substituent RA represented by RA2or RA4. In a particularly preferred embodiment, the heteroaryl group A is substituted with only one substituent RArepresented by RA3. Accordingly, in one embodiment, the heteroaryl group A is a heteroaryl group A* substituted with RA3and two further substituents RA2and RA4. In a preferred embodiment, the heteroaryl group A is a heteroaryl group A* substituted with RA3and one further substituent RA2or RA4. In a particularly preferred embodiment, the heteroaryl group is a heteroaryl group A* substituted only with RA3so that RA2and RA4are absent. As indicated above, RAis halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl- C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1- C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl. In a preferred embodiment, RAis C1-C4-alkyl, C1-C4-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In a more preferred embodiment, RAis C1-C4-alkyl, C1-C4-haloalkyl, 3- to 7-membered saturated carbocyclyl or carbocyclyl- C1-C2-alkyl, 6- to 8-membered saturated spiro-carbobicyclyl or carbobicyclyl-C1-C2- alkyl, 3- to 7-membered saturated heterocyclyl or heterocyclyl-C1-C2-alkyl, or 6- to 8- membered saturated spiro-heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RAis C1-C4-alkyl, C1-C2-haloalkyl, 3- to 6-membered saturated carbocyclyl or carbocyclyl- C1-C2-alkyl, 3- to 6-membered saturated heterocyclyl or heterocyclyl-C1-C2-alkyl, or 7- membered saturated spiro-heterobicyclyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RAis CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, cyclopropyl, cyclobutyl, oxetanyl, or a 7-membered saturated spiro-heterobicyclyl, wherein the aforementioned spiro- heterobicyclic ring comprises one heteroatom selected from O, N, or S, preferably O or N, more preferably O, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RAis any one of the following groups: CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, wherein the wavy line in each case marks the connection to the A group. In an even more preferred embodiment, RAis any one of the following groups: CH(CH3)2, CF3, wherein the wavy line in each case marks the connection to the A group. In an even more preferred embodiment, RAis any one of the following groups: wherein the wavy line marks the connection to the A group. In an even more preferred embodiment, wherein the wavy line marks the connection to the A group. In one particularly preferred embodiment, RAis CH(CH3)2. In another particularly preferred embodiment, RAis wherein the wavy line marks the connection to the A group. The same embodiments defined above for RAalso apply for RA2, RA3, and RA4representing different substituents RAat the heteroaryl group A. In particular as regards RA3, the same preferences as described above for RAare relevant. Thus, in a preferred embodiment, RA3is C1-C4-alkyl, C1-C4-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In a more preferred embodiment, RA3is C1-C4-alkyl, C1-C4-haloalkyl, 3- to 7-membered saturated carbocyclyl or carbocyclyl- C1-C2-alkyl, 6- to 8-membered saturated spiro-carbobicyclyl or carbobicyclyl-C1-C2- alkyl, 3- to 7-membered saturated heterocyclyl or heterocyclyl-C1-C2-alkyl, or 6- to 8- membered saturated spiro-heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RA3is C1-C4-alkyl, C1-C2-haloalkyl, 3- to 6-membered saturated carbocyclyl or carbocyclyl- C1-C2-alkyl, 3- to 6-membered saturated heterocyclyl or heterocyclyl-C1-C2-alkyl, or 7- membered saturated spiro-heterobicyclyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, preferably one or two, more preferably one, same or different heteroatoms selected from O, N, or S, preferably O or N, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RA3is CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, cyclopropyl, cyclobutyl, oxetanyl, or a 7-membered saturated spiro-heterobicyclyl, wherein the aforementioned spiro- heterobicyclic ring comprises one heteroatom selected from O, N, or S, preferably O or N, more preferably O, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl; preferably RYis Cl, F, or C1-C2-alkyl; more preferably RYis F or CH3; even more preferably RYis F. In an even more preferred embodiment, RA3is any one of the following groups: CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, , wherein the wavy line in each case marks the connection to the A group. In an even more preferred embodiment, RA3is any one of the following groups: CH(CH3)2, CF3, wherein the wavy line in each case marks the connection to the A group. In an even more preferred embodiment, RA3is any one of the following groups: wherein the wavy line marks the connection to the A group. In an even more preferred embodiment, wherein the wavy line marks the connection to the A group. In one particularly preferred embodiment, RA3is CH(CH3)2. In another particularly preferred embodiment, RA3is wherein the wavy line marks the connection to the A group. Thus, in one preferred embodiment, RA, in particular RA3, is cyclopropyl, wherein the cyclopropyl ring is unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In this context, preferably, RA, in particular RA3, is selected from the group consisting of (RA3-1), (RA3-5), (RA3-6), (RA3-6a), (RA3-6b), (RA3-7), (RA3-7a), (RA3-7b), (RA3-7c), and (RA3-7d). In one embodiment, RA, in particular RA3, is unsubstituted cyclopropyl (RA3-1). In another embodiment, RA, in particular RA3, is cyclopropyl substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In this context, RA, in particular RA3, is preferably selected from the group consisting of (RA3-5), (RA3- 6), (RA3-6a), (RA3-6b), (RA3-7), (RA3-7a), (RA3-7b), (RA3-7c), and (RA3-7d). In another preferred embodiment, RA, in particular RA3, is cyclobutyl, wherein the cyclobutyl ring is unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In this context, preferably, RA, in particular RA3, is selected from the group consisting of (RA3-2) and (RA3-4). In one embodiment, RA, in particular RA3, is unsubstituted cyclobutyl (RA3-2). In another embodiment, RA, in particular RA3, is cyclobutyl substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In this context, RA, in particular RA3, is preferably (RA3-4). In another preferred embodiment, RA, in particular RA3, is oxetanyl or a 6- to 8-membered, preferably 7-membered, saturated spiro-heterobicyclyl, wherein the aforementioned spiro- heterobicyclic ring comprises one heteroatom selected from O, N, or S, preferably O or N, more preferably O, wherein said N- and / or S-atoms are independently oxidized or non- oxidized, and wherein each of the aforementioned rings is independently unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In this context, preferably, RA, in particular RA3, is unsubstituted and is more preferably selected from the group consisting of (RA3-3) and (RA3- 8). In another preferred embodiment, RA, in particular RA3, is CH(CH3)2. In another preferred embodiment, RA, in particular RA3, is CF3. In a more preferred embodiment, RA, in particular RA3, is cyclopropyl, wherein the cyclopropyl ring is unsubstituted or substituted with one or more, preferably one or two, same or different substituents RY, wherein RYis F or CH3, preferably F. In a particularly preferred embodiment, RA, in particular RA3, is unsubstituted cyclopropyl, so that RA, in particular RA3, is the following group RA3-1 , wherein the wavy line marks the connection to the A group. As regards RA2, if present, the following preferences are further relevant. In a preferred embodiment, RA2is halogen, CN, C1-C2-alkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl. In a more preferred embodiment, RA2is halogen, CN, or C1-C2-alkyl. In an even more preferred embodiment, RA2is C1-C2-alkyl. In the most preferred embodiment, RA2is CH3. As indicated above, it is preferred in connection with the compounds of the present invention that a substituent RA2is not present at the heteroaryl group A or A*. As regards RA4, if present, the following preferences are further relevant. In a preferred embodiment, RA4is halogen, CN, C1-C2-alkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl. In a more preferred embodiment, RA4is halogen, CN, or C1-C2-alkyl. In an even more preferred embodiment, RA4is C1-C2-alkyl. In the most preferred embodiment, RA4is CH3. As indicated above, it is preferred in connection with the compounds of the present invention that a substituent RA4is not present at the heteroaryl group A or A*. In view of the above, the following meanings for the heteroaryl group A including the respective substituent RA3thereon according to embodiments C-1 to C-32 are preferred. Table C Of particular relevance are embodiments C-1, C-2, C-3, C-17, C-18, and C-19, more preferably C-3 and C-19, even more preferably C-3. Overall, in a particularly preferred embodiment of the invention, A wherein the wavy line in each case marks the connection to the remainder of the molecule. Thus, in a preferred embodiment, the compound of formula (I) is a compound of formula In one preferred embodiment, the compound of formula (I) is a compound of formula (Ia- In another preferred embodiment, the compound of formula (I) is a compound of formula (Ib*): Particularly preferred compounds of formula (I) are compounds of formula (Ia-T1*) or its tautomer (Ia-T2*). In one particularly preferred embodiment, the compound of formula (I) is a compound of formula (Ia-T1*). In another particularly preferred embodiment, the compound of formula (I) is a compound of formula (Ia-T2*). In connection with the compounds of formula (I) and the compounds of formula (Ia-T1), (Ia-T2), (Ib), (Ia-T1*), (Ia-T2*), (Ib*), preferably the compounds of formula (Ia-T1), (Ia-T2), (Ia-T1*), and (Ia-T2*), in particular (Ia-T1*) and (Ia-T2*), as well as in connection with the preferred embodiments regarding the heteroaryl group A or A* defined above, in particular A1-T1, A1-T2, A2-T1, A2-T2, A3, A4, A5, A6, A7, A8, A9, or A10, preferably A1-T1, A1-T2, or A10, especially in connection with any of the embodiments C1 to C32 of Table C, in particular A1-T1*, A1-T2*, or A10*, the following preferred embodiments regarding B and the substituents RB1to RB17thereon are relevant. As indicated above, in the compounds of formula (I), B is any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(RN), or -C1-C4-alkyl-N(RN)2; provided that at least one of RB2, RB3, and RB4is different from H; preferably each of RB2to RB4, RB7to RB9, and RB11to RB17is independently H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4- haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, or C1-C4-alkyl- S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4-dimethylaminoalkyl; provided that at least one of RB2, RB3, and RB4is different from H; X1is N or CRB6; preferably N; Y1is N or CRB7; preferably CRB7; Z1is N or CRB8; preferably CRB8; provided that one, but not more than one of X1, Y1, and Z1is N. In a more preferred embodiment, B is any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein X1, Y1, and Z1and each of RB1to RB14is as defined above or in the preferred embodiments defined below. In a more preferred embodiment, B is any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein X1, Y1, and Z1and each of RB1to RB14is as defined above or in the preferred embodiments defined below. In an even more preferred embodiment, B is any one of the following groups ; wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein X1, Y1, and Z1and each of RB1to RB10is as defined above or in the preferred embodiments defined below. In one particularly preferred embodiment, wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein each of RB1to RB5is as defined above or in the preferred embodiments defined below. In another particularly preferred embodiment, wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein X1, Y1, and Z1and each of RB6to RB10is as defined above or in the preferred embodiments defined below. Thus, in a preferred embodiment of the invention, the compound of formula (I) is a compound of formula (Ic) or (Id): wherein R1, RB2to RB4, RB7to RB9, and A are as described above for formula (I). Preferably, R1, RB2to RB4, and / or RB7to RB9are as defined in the preferred embodiments below and A is as defined in the preferred embodiments above. In a more preferred embodiment, A is A1- T1, A1-T2, or A10, preferably, A1-T1 or A1-T2. In a particularly preferred embodiment, A is A1-T1*, A1-T2*, or A10*, preferably, A1-T1* or A1-T2*. Further, it is particularly preferred that R1is CH3. In connection with ring B of the compounds of formula (I), in particular in connection with the preferred embodiments for ring B described above, as well as in connection with the compounds of formula (Ic) and (Id), the following preferences regarding the substituents RB2to RB4, RB7to RB9, and RB11to RB17are relevant. As indicated above, each of RB2to RB4, RB7to RB9, and RB11to RB17, if present, is independently H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4- alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(RN), or -C1-C4-alkyl-N(RN)2. In one preferred embodiment, each of RB2to RB4, RB7to RB9, and RB11to RB17, if present, is independently H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4- alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, or C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3),or C1-C4- dimethylaminoalkyl; provided that at least one of RB2, RB3, and RB4is different from H. In a more preferred embodiment, each of RB2to RB4, RB7to RB9, and RB11to RB17, if present, is independently H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In an even more preferred embodiment, each of RB2to RB4, RB7to RB9, and RB11to RB17, if present, is independently H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In an even more preferred embodiment, each of RB2to RB4, RB7to RB9, and RB11to RB17, if present, is independently H, Cl, F, CN, CH3, CHF2, OCH3, or CH2OH. Further, in connection with RB2to RB4, RB7to RB9, and RB11to RB17, the following preferences regarding RNare relevant. As indicated above, RNis C1-C4-alkyl. In a preferred embodiment, RNis C1-C2-alkyl. In a particularly preferred embodiment, RNis CH3. As regards RB2, RB3, and RB4of the phenyl group B1 as ring B, in particular in any of the preferred embodiments of ring B defined above, as well as the compounds of formula (Ic), the following preferences are particularly relevant. In a preferred embodiment, RB2is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2; RB3is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2; RB4is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2; provided that at least one of RB2, RB3, and RB4is different from H. In a more preferred embodiment, RB2is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB3is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB4is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; provided that at least one of RB2, RB3, and RB4is different from H. As indicated above, at least one of RB2, RB3, and RB4is different from H. Further, it is preferred in connection with B, in particular B1, that at least one of RB2, RB3, and RB4is H. Accordingly, in a preferred embodiment, B1 contains one or two substituents, i.e., at least one of RB2, RB3, and RB4is different from H and at least one of RB2, RB3, and RB4is H. In one embodiment, B1 contains one substituent, i.e., one of RB2, RB3, and RB4is different from H and two of RB2, RB3, and RB4are H. In another embodiment, B1 contains two substituents, i.e., two of RB2, RB3, and RB4are different from H and one of RB2, RB3, and RB4is H. Thus, in an even more preferred embodiment, RB2is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB3is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB4is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and provided that at least one of RB2, RB3, and RB4is different from H and one of RB2, RB3, and RB4is H. In an even more preferred embodiment, RB2is H, Cl, F, CN, CH3, CHF2, OCH3, or CH2OH; RB3is H, Cl, F, CN, CH3, CHF2, OCH3, CH2OH,; RB4is H, Cl, F, CN, CH3, CHF2, OCH3, or CH2OH; and provided that at least one of RB2, RB3, and RB4is different from H. In an even more preferred embodiment, RB2is H, Cl, F, CN, CH3, CHF2, OCH3, or CH2OH; RB3is H, Cl, F, CN, CH3, OCH3, or CH2OH; RB4is H, Cl, or F; provided that at least one of RB2, RB3, and RB4is different from H. Thus, if B is B1, in particular in the preferred embodiments for B defined above, B1 is preferably any one of the following groups more preferably (B1-a), (B1-b), or (B1-c);even more preferably ;wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB2, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB3, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB4, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; preferably, RB2, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB3, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB4, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; more preferably, RB2, if present, is Cl, F, CN, CH3, CHF2, OCH3, or CH2OH; RB3, if present, is Cl, F, CN, CH3, OCH3, or CH2OH; RB4, if present, is F. In a particularly preferred embodiment, B1 is B1-a. In another particularly preferred embodiment B1 is B1-c. In one embodiment, B is a group B1-a. In this connection, it is preferred that, RB2is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and RB4is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. More preferably, RB2is Cl, F, CN, CH3, CHF2, or OCH3; and RB4is Cl, F, CN, CH3, CHF2, or OCH3. Even more preferably, RB2is Cl, F, CN, CH3, CHF2, or OCH3; and RB4is Cl, F, or CN. In particularly preferred embodiments, B is therefore any one of the following groups: wherein the wavy line in each case marks the connection to the remainder of the molecule. In one embodiment, B is a group B1-b. In this connection, it is preferred that, RB2is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and RB3is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. More preferably, RB2is Cl, F, CN, CH3, CHF2, OCH3, or CH2OCH3; and RB3is Cl, F, CN, or CH3. More preferably, RB2is Cl, F, CN, CH3, CHF2, or OCH3; and RB3is Cl, F, or CH3. Even more preferably, RB2is Cl, F, CH3, or OCH3; and RB3is F. In particularly preferred embodiments, B is therefore any one of the following groups: wherein the wavy line in each case marks the connection to the remainder of the molecule. In one embodiment, B is a group B1-c. In this connection, it is preferred that, RB2is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. More preferably, RB2is Cl, F, CN, CH3, CHF2, OCH3, CH2OH, or CH2OCH3. Even more preferably, RB2is Cl, F, CN, CH3, OCH3, or CH2OH. In particularly preferred embodiments, B is therefore any one of the following groups: In one embodiment, B is a group B1-d. In this connection, it is preferred that, RB3is Cl, F, CN, CH3, OH, NH2, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. More preferably, RB3is Cl, F, CN, CH3, OCH3, or CH2OH. In particularly preferred embodiments, B is therefore any one of the following groups: As regards X1, Y1, Z1and RB7, RB8, and RB9of the pyridinyl group B2 as ring B, in particular in any of the preferred embodiments of ring B defined above, as well as of the compounds of formula (Id), the following preferences are particularly relevant. As indicated above, it is preferred in connection with B, in particular B2, that X1is N. Accordingly, preferably Y1is CRB7and Z1is CRB8and the pyridinyl group B2 is preferably the pyridinyl group B2*: wherein the wavy line marks the connection to the remainder of the molecule. As regards the substituents RB7, RB8, and RB9of B2 and B2*, as well as of the compounds of formula (Id), it is preferred that RB7is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB8is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB9is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; In a more preferred embodiment, RB7is H, Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB8is H, Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB9is H, Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In an even more preferred embodiment, RB7is H, Cl, F, CH3, OCH3, or CH2OH; RB8is H, Cl, F, CH3, OCH3, or CH2OH; RB9is H, Cl, F, CH3, OCH3, or CH2OH. Further, it is preferred in connection with B2 and B2* that at least one, preferably one or two, of RB7, RB8, and RB9being present is H. Accordingly, in a preferred embodiment, B2, in particular B2*, contains none, one, or two, preferably one or two, more preferably one, substituents, i.e., at least one, preferably one or two, more preferably two, of RB7, RB8, and RB9being present is H. In one embodiment, B2, in particular B2*, contains one substituent, i.e., one of RB7, RB8, and RB9being present is different from H and two of RB7, RB8, and RB9being present are H. In another embodiment, B2, in particular B2*, contains two substituents, i.e., two of RB7, RB8, and RB9being present are different from H and one of RB7, RB8, and RB9being present is H. In a particularly preferred embodiment, the one or two, preferably one, substituent at B2, in particular B2*, is at position RB7or RB9, i.e., Z1is N or CRB8, wherein RB8is H, preferably Z1is CRB8, wherein RB8is H. Thus, if B is B2 or B2*, in particular in any of the preferred embodiments for B defined above, B2 or B2* is preferably any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB7, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB8, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB9, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; preferably, RB7, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB8, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB9, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. more preferably, RB7, if present, is Cl, F, CH3, OCH3, or CH2OH; RB8, if present, is Cl, F, CH3, OCH3, or CH2OH; RB9, if present, is Cl, F, CH3, OCH3, or CH2OH. In a particularly preferred embodiment, B2 or B2* is B2*-d. In another particularly preferred embodiment B2 or B2* is B2*-f. In one embodiment, B is a group B2*-a. In this connection, it is preferred that, RB7is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and RB9is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB7is CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3; and RB9is CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3. In an even more preferred embodiment, RB7is CH3, N(CH3)2, or OCH3; RB9is CH3, N(CH3)2, or OCH3. In another embodiment, B is a group B2*-b. In this connection, it is preferred that, RB7is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and RB8is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB7is CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3; and RB8is CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3. In an even more preferred embodiment, RB7is CH3, N(CH3)2, or OCH3; RB8is CH3, N(CH3)2, or OCH3. In another embodiment, B is a group B2*-c. In this connection, it is preferred that, RB9is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; and RB8is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB9is Cl, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3; and RB8is CN, N(CH3)2, CH3, CHF2, CF3, OCH3, or CH2OCH3. In a more preferred embodiment, RB9is Cl, CH3, N(CH3)2, or OCH3; RB8is CH3, N(CH3)2, or OCH3. In one particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another embodiment, B is a group B2*-d. In this connection, it is preferred that, RB9is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB9is Cl, F, CH3, N(CH3)2, OCH3, or CH2OH. In a more preferred embodiment, RB9is Cl or CH3. In particularly preferred embodiments, B is therefore any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule. In another embodiment, B is a group B2*-e. In this connection, it is preferred that, RB8is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB9is Cl, F, CH3, N(CH3)2, OCH3, or CH2OH. In an even more preferred embodiment, RB9is F or OCH3. In particularly preferred embodiments, B is therefore any one of the following groups , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another embodiment, B is a group B2*-f. In this connection, it is preferred that, RB7is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. In a more preferred embodiment, RB7is Cl, F, CH3, N(CH3)2, OCH3, or CH2OH. In an even more preferred embodiment, RB7is Cl, CH3, or CH2OH. In particularly preferred embodiments, B is therefore any one of the following groups wherein the wavy line in each case marks the connection to the remainder of the molecule. In another embodiment, B is an unsubstituted pyridinyl group B2. In this context, B is in one embodiment any one of the following groups ,wherein the wavy line in each case marks the connection to the remainder of the molecule. As regards RB11of the thiazole group B3, the following preferences are relevant. In a preferred embodiment, RB11is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB11is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB11is H, Cl, CN, or CH3. In one particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. As regards RB12of the thiazole group B4, the following preferences are relevant. In a preferred embodiment, RB12is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB12is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB12is H, Cl, CN, or CH3. In one particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. As regards RB13of the thiazole group B5, the following preferences are relevant. In a preferred embodiment, RB13is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB13is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB13is H, Cl, CN, or CH3. In one particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, B is therefore the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. As regards RB14of the thiazole group B6, the following preferences are relevant. In a preferred embodiment, RB14is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB14is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB14is H, Cl, CN, or CH3. In one particularly preferred embodiment, RB14is Cl so that B is the following group wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, RB14is CH3so that B is the following group wherein the wavy line in each case marks the connection to the remainder of the molecule. In another particularly preferred embodiment, RB14is H so that B is the following group , wherein the wavy line in each case marks the connection to the remainder of the molecule. As regards RB11and RB12of the thiazole group B10, the following preferences are relevant. In a preferred embodiment, RB11is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2; and RB12is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB11is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3; and RB12is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB11is H, Cl, CN, or CH3. RB12is H, Cl, CN, or CH3. In a particularly preferred embodiment, one of RB11and RB12is H, and the other one of RB11and RB12is H, Cl, or CH3. Accordingly, the thiazole group B10 is preferably a thiazole group B3 or B4. As regards RB15of the thiophene group B7, the following preferences are relevant. In a preferred embodiment, RB15is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB15is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB15is H, Cl, CN, or CH3. As regards RB16of the thiophene group B8, the following preferences are relevant. In a preferred embodiment, RB16is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB16is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB16is H, Cl, CN, or CH3. As regards RB17of the thiophene group B9, the following preferences are relevant. In a preferred embodiment, RB17is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB17is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB17is H, Cl, CN, or CH3. As regards RB11and RB12of the thiophene group B11, the following preferences are relevant. In a preferred embodiment, RB11is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2; and RB12is H, Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, cyclopropyl, cyclobutyl, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, CH2NH(CH3), or CH2N(CH3)2. In a more preferred embodiment, RB11is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3; and RB12is H, Cl, CN, CH3, cyclopropyl, CHF2, or OCH3. In an even more preferred embodiment, RB11is H, Cl, or CH3. RB12is H, Cl, or CH3. In a particularly preferred embodiment, one of RB15and RB16is H, and the other one of RB15and RB16is H, Cl, or CH3. Accordingly, the thiophene group B11 is preferably a thiophene group B7 or B8. Thus, in a preferred embodiment of the present invention, B is any one of the following groups g), even more preferably,

[0028] wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB2to RB4, RB7to RB9, and RB11to RB17are as defined above for B1-a, B1-b, B1-c, B1-d, B2*-a, B2*-b, B2*-c, B2*-d, B2*-e, B2*-f, B3, B4, B5, B6, B7, B8, or B9. In one more preferred embodiment, B is any one of the following groups even more preferably, wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB2to RB4are as defined above for B1-a, B1-b, B1-c, or B1-d, preferably, RB2, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB3, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB4, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; more preferably, RB2, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB3, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB4, if present, is Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; even more preferably, RB2, if present, is Cl, F, CN, CH3, CHF2, OCH3, or CH2OH; RB3, if present, is Cl, F, CN, CH3, OCH3, or CH2OH; RB4, if present, is F. In a particularly preferred embodiment, B1 is B1-a. In another particularly preferred embodiment B1 is B1-c. In another more preferred embodiment, even more preferably, wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB7to RB9are as defined above for B2*-a, B2*-b, B2*-c, B2*-d, B2*-e, or B2*-f, preferably RB7, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB8, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; RB9, if present, is Cl, F, CN, OH, NH2, NH(CH3), N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, CH2NH2, or CH2N(CH3)2; more preferably, RB7, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB8, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3; RB9, if present, is Cl, F, CN, N(CH3)2, CH3, CHF2, CF3, OCH3, CH2OH, or CH2OCH3. even more preferably, RB7, if present, is Cl, F, CH3, OCH3, or CH2OH; RB8, if present, is Cl, F, CH3, OCH3, or CH2OH; RB9, if present, is Cl, F, CH3, OCH3, or CH2OH. In a particularly preferred embodiment, B2 or B2* is B2*-d. In another particularly preferred embodiment B2 or B2* is B2*-f. In a preferred embodiment of the invention, the compound of formula (I) is thus a compound of formula (Ic-1), (Ic-2), (Ic-3), (Id-1), or (Id-2): wherein R1, RB2, RB4, RB7, RB9, and A are as described above for formula (I). Preferably, R1is as defined in the preferred embodiments below and A, RB2, RB4, RB7, and / or RB9are as defined in the preferred embodiments above. In a preferred embodiment, A is A1-T1, A1-T2, or A10, preferably, A1-T1 or A1-T2. In a particularly preferred embodiment, A is A1-T1*, A1- T2*, or A10*, preferably, A1-T1* or A1-T2*. Further, it is particularly preferred that R1is CH3. In particularly preferred embodiments, B is a moiety selected from the group consisting of , wherein the wavy line in each case marks the connection to the remainder of the molecule. In even more preferred embodiments, wherein the wavy line in each case marks the connection to the remainder of the molecule. In view of the above, the following meanings for ring B according to embodiments D-1 to D-80 of Table D are preferred. Table D

[0029] Particularly preferred are embodiments D1, D3, D8, D10, D21-D32, D40-D48, D56-D59, and D62-D66 of Table D. In connection with the compounds of formula (I) and the compounds of formula (Ia-T1), (Ia- T2), (Ib), (Ia-T1*), (Ia-T2*), (Ib*), (Ic), (Id), (Ic-1), (Ic-2), (Ic-3), (Id-1), and (Id-2), in particular the compounds of formula (Ia-T1*), (Ia-T2*), (Ic-1), (Ic-2), (Ic-3), (Id-1), and (Id- 2), as well as in connection with the preferred embodiments regarding the heteroaryl group A or A* defined above, in particular A1-T1, A1-T2, A2-T1, A2-T2, A3, A4, A5, A6, A7, A8, A9, or A10, preferably A1-T1, A1-T2, or A10, especially any one of embodiments C1 to C32 of Table C, in particular A1-T1* and A1-T2*, as well as in connection with the preferred embodiments of B defined above, in particular B1-a, B1-b, B1-c, B1-d, B2*-a, B2*-b, B2*-c, B2*-d, B2*-e, B2*-f, B2*-g, B3, B4, B5, and B6, in particular, B1-a, B1-c, B2*-d, and B2*-f, especially any one of embodiments D21-D80 of Table D, in particular any one of D21-D32, D40-D48, D56-D59, and D62-D66 of Table D, the following preferred embodiments regarding the substituents R1are relevant. As indicated above, in the compounds of formula (I), R1is H or C1-C4-alkyl. In a preferred embodiment, R1is H or C1-C2-alkyl. In a more preferred embodiment, R1is H or CH3. In a particularly preferred embodiment, R1is CH3. In one embodiment of the invention, R1is H. Such compounds of formula (I) are referred to as compounds of formula (I.1). In another embodiment of the invention, R1is C1-C4-alkyl. In a more preferred embodiment, R1is C1-C2-alkyl. In a particularly preferred embodiment, R1is CH3. Such compounds of formula (I) are referred to as compounds of formula (I.2). If R1is not H, in one embodiment of the invention, the compound of formula (I) is a compound of formula (IA) wherein A and B are as defined above for formula (I), preferably as defined in the preferred embodiments above, and R1is C1-C4-alkyl, preferably C1-C2-alkyl, more preferably CH3. In one particularly preferred embodiment, R1is CH3. Such compounds are referred to as compounds of formula (IA.2). In one embodiment, it is preferred in connection with the compounds of formula (IA) and (IA.2) that A is A1-T1, A1-T2, or A10, especially any one of embodiments C1 to C32 of Table C, preferably A1-T1*, A1-T2*, or A10*, in particular A1-T1* or A1-T2*. In another preferred embodiment, it is preferred in connection with the compounds of formula (IA) and (IA.2) that B is any one of B1-a, B1-b, B1-c, B1-d, B2*-a, B2*-b, B2*-c, B2*-d, B2*-e, B2*-f, B2*- g, B3, B4, B5, or B6, in particular any one of B1-a, B1-c, B2*-d, or B2*-f, especially any one of embodiments D21-D80 of Table D, in particular any one of D21-D32, D40-D48, D56-D59, and D62-D66 of Table D. In another embodiment of the invention, the compound of formula (I) is a compound of formula (IB) , wherein A and B are as defined above for formula (I), preferably as defined in the preferred embodiments above, and R1is C1-C4-alkyl, preferably C1-C2-alkyl, more preferably CH3. In one particularly preferred embodiment, R1is CH3. Such compounds are referred to as compounds of formula (IB.2). In one embodiment, it is preferred in connection with the compounds of formula (IB) and (IB.2) that A is A1-T1, A1-T2, or A10, especially any one of embodiments C1 to C32 of Table C, preferably A1-T1*, A1-T2*, or A10*, in particular A1-T1* or A1-T2*. In another preferred embodiment, it is preferred in connection with the compounds of formula (IB) and (IB.2) that B is any one of B1-a, B1-b, B1-c, B1-d, B2*-a, B2*-b, B2*-c, B2*-d, B2*-e, B2*-f, B2*- g, B3, B4, B5, or B6, in particular any one of B1-a, B1-c, B2*-d, or B2*-f, especially any one of embodiments D21-D80 of Table D, in particular any one of D21-D32, D40-D48, D56-D59, and D62-D66 of Table D. In certain embodiments of the invention, in the compounds of formula (I), the following combinations of embodiments are preferred: Table 1 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 2 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 3 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 4 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 5 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 6 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 7 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 8 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 9 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 10 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 11 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-6 and B corresponds in each case to one row of Table D. Table 12 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-6 and B corresponds in each case to one row of Table D. Table 13 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-6a or RA3-6b, and B corresponds in each case to one row of Table D. Table 14 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-6a or RA3-6b, and B corresponds in each case to one row of Table D. Table 15 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-7 and B corresponds in each case to one row of Table D. Table 16 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-7 and B corresponds in each case to one row of Table D. Table 17 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-7a or RA3-7b and B corresponds in each case to one row of Table D. Table 18 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-7a or RA3-7b and B corresponds in each case to one row of Table D. Table 19 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-7c or RA3-7d and B corresponds in each case to one row of Table D. Table 20 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-7c or RA3-7d and B corresponds in each case to one row of Table D. Table 21 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 22 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 23 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is CF3, and B corresponds in each case to one row of Table D. Table 24 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is CF3, and B corresponds in each case to one row of Table D. Table 25 Compounds of formula (I.1), in which A is A1-T1 or A1-T2, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 26 Compounds of formula (I.2), in which A is A1-T1 or A1-T2, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 27 Compounds of formula (I.1), in which A is A10, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 28 Compounds of formula (I.2), in which A is A10, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 29 Compounds of formula (I.1), in which A is A10, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 30 Compounds of formula (I.2), in which A is A10, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 31 Compounds of formula (I.1), in which A is A10, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 32 Compounds of formula (I.2), in which A is A10, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 33 Compounds of formula (I.1), in which A is A10, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 34 Compounds of formula (I.2), in which A is A10, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 35 Compounds of formula (I.1), in which A is A10, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 36 Compounds of formula (I.2), in which A is A10, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 37 Compounds of formula (I.1), in which A is A10, RA3is RA3-6 and B corresponds in each case to one row of Table D. Table 38 Compounds of formula (I.2), in which A is A10, RA3is RA3-6 and B corresponds in each case to one row of Table D. Table 39 Compounds of formula (I.1), in which A is A10, RA3is RA3-6a or RA3-6b, and B corresponds in each case to one row of Table D. Table 40 Compounds of formula (I.2), in which A is A10, RA3is RA3-6a or RA3-6b, and B corresponds in each case to one row of Table D. Table 41 Compounds of formula (I.1), in which A is A10, RA3is RA3-7 and B corresponds in each case to one row of Table D. Table 42 Compounds of formula (I.2), in which A is A10, RA3is RA3-7 and B corresponds in each case to one row of Table D. Table 43 Compounds of formula (I.1), in which A is A10, RA3is RA3-7a or RA3-7b and B corresponds in each case to one row of Table D. Table 44 Compounds of formula (I.2), in which A is A10, RA3is RA3-7a or RA3-7b and B corresponds in each case to one row of Table D. Table 45 Compounds of formula (I.1), in which A is A10, RA3is RA3-7c or RA3-7d and B corresponds in each case to one row of Table D. Table 46 Compounds of formula (I.2), in which A is A10, RA3is RA3-7c or RA3-7d and B corresponds in each case to one row of Table D. Table 47 Compounds of formula (I.1), in which A is A10, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 48 Compounds of formula (I.2), in which A is A10, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 49 Compounds of formula (I.1), in which A is A10, RA3is CF3, and B corresponds in each case to one row of Table D. Table 50 Compounds of formula (I.2), in which A is A10, RA3is CF3, and B corresponds in each case to one row of Table D. Table 51 Compounds of formula (I.1), in which A is A10, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 52 Compounds of formula (I.2), in which A is A10, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 53 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 54 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 55 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 56 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 57 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 58 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-6, RA3-6a, or RA3-6b, and B corresponds in each case to one row of Table D. Table 59 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-7, RA3-7a, RA3-7b, RA3- 7c, or RA3-7d, and B corresponds in each case to one row of Table D. Table 60 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 61 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is CF3, and B corresponds in each case to one row of Table D. Table 62 Compounds of formula (I.A.2), in which A is A1-T1 or A1-T2, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 63 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 64 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 65 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 66 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 67 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 68 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-6, RA3-6a, or RA3-6b, and B corresponds in each case to one row of Table D. Table 69 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-7, RA3-7a, RA3-7b, RA3-7c, or RA3- 7d, and B corresponds in each case to one row of Table D. Table 70 Compounds of formula (I.A.2), in which A is A10, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 71 Compounds of formula (I.A.2), in which A is A10, RA3is CF3, and B corresponds in each case to one row of Table D. Table 72 Compounds of formula (I.A.2), in which A is A10, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 73 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 74 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 75 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 76 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 77 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 78 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-6, RA3-6a, or RA3-6b, and B corresponds in each case to one row of Table D. Table 79 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-7, RA3-7a, RA3-7b, RA3- 7c, or RA3-7d, and B corresponds in each case to one row of Table D. Table 80 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 81 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is CF3, and B corresponds in each case to one row of Table D. Table 82 Compounds of formula (I.B.2), in which A is A1-T1 or A1-T2, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. Table 83 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-1, and B corresponds in each case to one row of Table D. Table 84 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-2, and B corresponds in each case to one row of Table D. Table 85 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-3, and B corresponds in each case to one row of Table D. Table 86 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-4, and B corresponds in each case to one row of Table D. Table 87 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-5, and B corresponds in each case to one row of Table D. Table 88 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-6, RA3-6a, or RA3-6b, and B corresponds in each case to one row of Table D. Table 89 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-7, RA3-7a, RA3-7b, RA3-7c, or RA3- 7d, and B corresponds in each case to one row of Table D. Table 90 Compounds of formula (I.B.2), in which A is A10, RA3is RA3-8, and B corresponds in each case to one row of Table D. Table 91 Compounds of formula (I.B.2), in which A is A10, RA3is CF3, and B corresponds in each case to one row of Table D. Table 92 Compounds of formula (I.B.2), in which A is A10, RA3is CH(CH3)2, and B corresponds in each case to one row of Table D. In a particularly preferred embodiment of the invention, the compound of formula (I) is selected from the group consisting of (R)-N-(5-(tert-butyl)-1H-pyrazol-3-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, (S)-N-(5-(tert-butyl)-1H-pyrazol-3-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-(tert-butyl)-1H-pyrazol-3-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-(tert-butyl)-1H-pyrazol-5-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, (S)-N-(3-(tert-butyl)-1H-pyrazol-5-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, N-(3-(tert-butyl)-1H-pyrazol-5-yl)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropylthiazol-2-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(2-chlorothiazol-5-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(2-chlorothiazol-5-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(2-methylthiazol-5-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(2-methylthiazol-5-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-5-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-5-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-2-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(5-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(5-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(4-fluoro-3-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(4-(hydroxymethyl)phenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(3-(hydroxymethyl)phenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(4-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(m-tolyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(p-tolyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(3-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(5-fluoropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(4-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-isopropylthiazol-2-yl)acetamide, 2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-(trifluoromethyl)-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropylthiazol-2-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, and N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide. In an even more preferred embodiment of the invention, the compound of formula (I) is selected from the group consisting of N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(3-(hydroxymethyl)phenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(3-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropylthiazol-2-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, and N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide. In one particularly preferred embodiment of the invention, the compound of formula (I) is selected from the group consisting of: (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, and (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide. In another particularly preferred embodiment of the invention, the compound of formula (I) is selected from the group consisting of (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, and (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide. In a particularly preferred embodiment of the invention, the compound of formula (I) is selected from the group consisting of

[0030]

[0031] . The term "cancer cell" as used herein means a tumor cell having an ability to proliferate depending on a particular oncogene expressed in the cancer cell. The cancer cell may include a primary cultured cell, a cell line, or a cancer stem cell. As used herein, the "dependence (depending)" concerning the proliferation of the cell refers to the state of the oncogene addiction or the addiction, where the cell proliferates depending on the particular oncogene. Whether or not the cell proliferates depending on the particular oncogene can be confirmed by treating the cell with an inhibitor of the particular oncogene and then evaluating a proliferation ability of the treated cell. For example, the cell as used in context of the method of the invention may be a cancer cell. In one aspect, the present invention relates to a compound for use in medicine. The term "medicine" as used herein is intended to be a generic term inclusive of prescription and non-prescription medications. The compound for use in medicine should be understood as being useful in maintaining health or promoting recovery from a disease, preferably cancer. Further, the term "medicine" includes medicine in any form, including, without limitation, e.g., pills, salves, creams, powders, ointments, capsules, injectable medications, drops, vitamins and suppositories. The scope of this invention is not limited by the type, form or dosage of the medicine. The compounds as described herein and in the context of the present invention, may be for use in treating or preventing cancer, metabolic disorders, neurologic disorders or infectious diseases. In this regard, the compounds as described herein and in the context of the present invention may degrade proteins associated with cancer, metabolic disorders, neurologic disorders or infectious diseases directly or indirectly via the E3 ligase as described herein. For example, proteins associated with cancer, metabolic disorders, neurologic disorders or infectious diseases may be downregulated upon degradation of CCNK by the E3 ligase as shown by the proteomics profiling analysis in example 5 of WO 2021 / 074414. Particularly, proteins associated with neurological disorder such as HECTD1, MBP and FEM1A are downregulated upon degradation of CCNK. As another example, proteins associated with metabolic diseases such as HMMR, LMNA and TMPO are also downregulated upon degradation of CCNK. As still another example, proteins associated with infectious disease such as ICAM2, CALCOCO2 and CDC6 are downregulated upon degradation of CCNK. As yet still another example, cancer associated proteins such as BUB1, BUB1B, MCM10, CDCA7 and CDC6 are also all downregulated upon degradation of CCNK. Thus, proteins that are downregulated upon degradation of CCNK involve proteins associated with cancer, metabolic disorders, neurologic disorders or infectious diseases. In one aspect of the present invention, the chemical compound or agent is for use in the treatment of cancer, wherein preferred cancers are listed above. A "disorder," a "disease," or a "condition," as used interchangeably herein, is any condition that would benefit from treatment with a composition (e.g., a pharmaceutical composition) described herein, e.g., a composition (e.g., a pharmaceutical composition) that includes the fusion protein of the present invention. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. The term "pharmaceutical composition" or "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the pharmaceutical composition would be administered. The term "pharmaceutically acceptable", as used in connection with compositions of the invention, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human). The term "pharmaceutically acceptable" may also mean approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans. A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition or formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. Such pharmaceutically acceptable carriers may be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by A.R. Gennaro, 20th Edition. As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. "Alleviation," "alleviating," or equivalents thereof, refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to ameliorate, prevent, slow down (lessen), decrease or inhibit a disease or condition, e.g., the formation of atherosclerotic plaques. Those in need of treatment include those already with the disease or condition as well as those prone to having the disease or condition or those in whom the disease or condition is to be prevented. The term "cancer" as used herein refers to any malignant tumor in the aforementioned tissue and cell type. Examples of the cancer may include a cancer which can be caused by an abnormal adherent cell, or a cancer which can be caused by an abnormal blood cell (e.g., leukemia, lymphoma, multiple myeloma). In one embodiment, the cancer is a solid tumor cancer. In another embodiment, the cancer is selected from the group consisting of leukemia, particularly acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), and a chronic leukemia including chronic myeloid leukemia; lymphoma, particularly Non-Hodgkin Lymphoma and Hodgkin Lymphoma; head and neck cancer; esophageal cancer; adenoid cystic carcinoma; osteosarcoma; ovarian cancer; Ewing’s sarcoma; lung cancer; neuroblastoma; gastrointestinal cancer; endometrial cancer; cervical cancer; medulloblastoma; prostate cancer; esophagus cancer; breast cancer; thyroid cancer; meningioma; liver cancer; colorectal cancer; pancreatic cancer; chondrosarcoma; osteosarcoma; and kidney cancer. As also discussed above, a cancer to be treated in accordance with the present invention and by the means and methods provided herein may be cancer associated with cell cycle modulators, like cyclin-dependant kinases or transcriptional kinases, like e.g. CDK12, CDK13 and / or cyclins, like CCNK. As used herein a "cancer associated with CDK12, CDK13 and / or CCNK" also includes a cancer associated with a complex of CDK12 / 13 and CCNK. The same applies, mutatis mutantis, for other disorders discussed herein, like neurological disorders / diseases, matabolic disorders / diseases, and / or infectious diseases. Also these disease may be, in context of this invention, associated with cell cycle modulators, like cyclin-dependant kinases or transcriptional kinases, like e.g. CDK12, CDK13 and / or cyclins, like CCNK. Degradation of CCNK has been described to induce genomic instability of cancer, such as of prostate cancer (see Wu et al 2018, Cell.2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016 / j.cell.2018.04.034) and has been suggested to be effective in cancers associated with mutations in DNA damage response genes such as those described in Table 1 of Lord et al 2016, Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038 / nrc.2015.21. Epub 2016 Jan 18. Further, CCNK degradation has been described to be particularly effective in cancers associated with increased levels of cyclin E1. Thus, as described herein, a cancer associated with cell-cycle modulators, like CDK12, CDK13 and / or CCNK includes, but is not limited, to cancer with an overexpression of cyclin E1 such as breast cancer, ovarian cancer, melanoma, bladder cancer, gastric cancer, stomach adenocarcinoma, lung squamous cancer, lung adenocarcinoma, glioblastoma multiforme and colorectal cancer; see Lei et al.; Nat Commun. 2018 May 14;9(1):1876. The "cancer" in cancer-related terms such as terms "cancer cell" and "cancer gene (oncogene)" can also mean the same meaning. The cancer cell can be derived from any mammalian species. Such a mammalian species may include, for example, humans, monkeys, cattle, swines, mice, rats, guinea pigs, hamsters, and rabbits. The mammalian species is preferably the human in terms of clinical application. Therefore, the cancer cell may be a cancer cell isolated from a patient with cancer or a cancer cell derived therefrom. The cancer cell may be a cell not infected with virus or a cell infected with virus. Examples of a carcinogenic virus capable of infecting the cell may include Epstein Barr virus, hepatitis virus, human papilloma virus, human T cell leukemia virus, and Kaposi sarcoma-associated herpes virus. The cancer cell may also be a cancer cell derived from an embryonic stem cell, a somatic stem cell, or an artificial stem cell (e.g., iPS cell) produced from a normal cell. The cancer cell from which the artificial cell of the present invention is derived can express an inherent oncogene. As used herein, the term "inherent oncogene" means an oncogene responsible for proliferation of the cancer cell, which is expressed by the cancer cell that can be used as a material in the establishment of the artificial cell of the present invention. For example, CDK12, CDK13 and / or CCNK can play a role in proliferation of cancer including but not limited to breast cancer, ovarian cancer, melanoma, bladder cancer, gastric cancer, stomach adenocarcinoma, lung squamous cancer, lung adenocarcinoma, glioblastoma multiforme and colorectal cancer. In one aspect, the present invention further relates to a method treating cancer comprising administering the chemical compound or agent to a patient having cancer. For example, the compound may be a compound binding to one or more protein(s) to be degraded, wherein the one or more protein(s) are proteins associated with cancer and may be a kinase such as a kinase selected from the group consisting of cyclin-dependent kinases and / or transcriptional kinases, like CDK12, CDK13 and / or cyclins, like CCNK. In this context, the invention may relate to a method for treating cancer comprising administering the chemical compound or agent to a patient having cancer, wherein the compound may be a compound binding to one or more protein(s) selected from the group consisting of CDK12, CDK13 and / or CCNK. For example, said chemical compound or agent is used for the treatment of cancer, wherein said cancer may be selected from lymphoma (in particular Non-Hodgkin Lymphoma and Hodgkin Lymphoma), liver cancer, breast cancer, neuroblastoma, cervical cancer, Ewing’s sarcoma, lung cancer, ovarian cancer, melanoma, bladder cancer, head and neck cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, stomach adenocarcinoma, lung squamous cancer, lung adenocarcinoma, glioblastoma multiforme and colorectal cancer. A “solid tumor cancer” or “solid cancer” is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Thus, the term “solid tumor cancer” refers to malignant solid tumors. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumor cancers are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors. A "patient" or "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, the patient, individual, or subject is a human. In one embodiment, the patient may be a "cancer patient," i.e. one who is suffering or at risk for suffering from one or more symptoms of cancer. It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the causative mechanism and severity of the particular disease undergoing therapy. As used herein, the terms "optional", "optionally" and "may" denote that the indicated feature may be present but can also be absent. Whenever the term "optional", "optionally" or "may" is used, the present invention specifically relates to both possibilities, i.e., that the corresponding feature is present or, alternatively, that the corresponding feature is absent. For example, the expression "X is optionally substituted with Y" (or "X may be substituted with Y") means that X is either substituted with Y or is unsubstituted. Likewise, if a component of a composition is indicated to be "optional", the invention specifically relates to both possibilities, i.e., that the corresponding component is present (contained in the composition) or that the corresponding component is absent from the composition. It is to be understood that where a list of groups is preceded by the expression "optionally substituted", the expression "optionally substituted" applies to each one of the respective groups in that list, not just to the first item in the list. As used herein, the term "halogen" refers to fluoro (–F), chloro (–Cl), bromo (–Br), or iodo As used herein, the term "alkyl" refers to a monovalent saturated acyclic (i.e., non-cyclic) hydrocarbon group which may be linear or branched. Accordingly, an "alkyl" group does not comprise any carbon-to-carbon double bond or any carbon-to-carbon triple bond. The term "alkyl" preferably refers to a "C1-6alkyl". A "C1-6alkyl" denotes an alkyl group having 1 to 6 carbon atoms. Preferred exemplary alkyl groups are methyl, ethyl, propyl (e.g., n-propyl or isopropyl), or butyl (e.g., n-butyl, isobutyl, sec-butyl, or tert-butyl). Unless defined otherwise, the term "alkyl" more preferably refers to C1-4alkyl, more preferably to methyl or ethyl, and even more preferably to methyl. As used herein, the term "alkoxy" refers to "–O– alkyl", wherein "alkyl" is as defined above. The term “alkoxyalkyl” as used herein refers to an alkoxy group as defined herein having usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, which is bonded via an alkyl group as defined herein having usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, to the remainder of the molecule. Thus, it refers to an alkyl group, which is bonded via oxygen to a further alkyl group, which is then bonded to the remainder of the molecule, i.e, "–alkyl–O– alkyl”. Examples of an alkoxyalkyl group are methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, and the like. The term “dimethylaminoalkyl” as used herein refers to a dimethylamino group (N(CH3)2), which is bonded via an alkyl group as defined herein having usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, to the remainder of the molecule, i.e., "–alkyl–N(CH3)2”. The term “aminoalkyl” as used herein refers to an amino group (NH2), which is bonded via an alkyl group as defined herein having usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, to the remainder of the molecule, i.e., "– alkyl–NH2”. The term “hydroxyalkyl” as used herein refers to a hydroxy group (OH), which is bonded via an alkyl group as defined herein having usually from 1 to 4 carbon atoms, preferably 1 to 2 carbon atoms, more preferably 1 carbon atom, to the remainder of the molecule, i.e., "– alkyl–OH”. As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more (preferably 1 to 6, more preferably 1 to 3) halogen atoms which are selected independently from fluoro, chloro, bromo and iodo, and are preferably all fluoro atoms. It will be understood that the maximum number of halogen atoms is limited by the number of available attachment sites and, thus, depends on the number of carbon atoms comprised in the alkyl moiety of the haloalkyl group. "Haloalkyl" may, e.g., refer to -CF3, -CHF2, -CH2F, -CF2-CH3, -CH2-CF3, -CH2-CHF2, -CH2-CF2-CH3, -CH2-CF2-CF3, or -CH(CF3)2. As used herein, the term "haloalkoxy" refers to "–O–haloalkyl", wherein "haloalkyl" is as defined above. As used herein, the term "heteroalkyl" refers to an alkyl group in which one or two of the – CH2– groups have been replaced each independently by a group selected from –O–, –S– and –N(C1-6alkyl)–. A preferred example is an alkoxy group such as methoxy. As used herein, the term "alkenyl" refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g., one or two) carbon-to-carbon double bonds while it does not comprise any carbon-to-carbon triple bond. The term "C2-6alkenyl" denotes an alkenyl group having 2 to 6 carbon atoms. Preferred exemplary alkenyl groups are ethenyl, propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl, or prop-2-en-1-yl), butenyl, butadienyl (e.g., buta-1,3-dien-1-yl or buta-1,3-dien-2-yl), pentenyl, or pentadienyl (e.g., isoprenyl). Unless defined otherwise, the term "alkenyl" preferably refers to C2-6alkenyl, more preferably C2-4alkenyl. As used herein, the term "alkynyl" refers to a monovalent unsaturated acyclic hydrocarbon group which may be linear or branched and comprises one or more (e.g., one or two) carbon-to-carbon triple bonds and optionally one or more carbon-to-carbon double bonds. The term "C2-6alkynyl" denotes an alkynyl group having 2 to 6 carbon atoms. Preferred exemplary alkynyl groups are ethynyl, propynyl, or butynyl. Unless defined otherwise, the term "alkynyl" preferably refers to C2-6alkynyl, more preferably C2-4alkynyl. As used herein, the term "aryl" refers to a monocyclic aromatic hydrocarbon ring group. Unless defined otherwise, an "aryl" preferably has 6 to 14 ring atoms, more preferably 6 to 10 ring atoms, and most preferably refers to phenyl. As used herein, the term "bicyclic aryl" refers to an aromatic hydrocarbon ring group, containing two, bridged or fused ring systems containing at least one aromatic ring (e.g., ring systems composed of two fused rings, wherein at least one of these fused rings is aromatic; or bridged ring systems composed of two rings, wherein at least one of these bridged rings is aromatic). "Bicyclic aryl" may, e.g., refer to naphthyl. Unless defined otherwise, an "bicyclic aryl" preferably has 10 ring atoms. As used herein, the term "heteroaryl" refers to a monocyclic aromatic ring group, wherein said aromatic ring group comprises one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may optionally be oxidized, and further wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group). "Heteroaryl" may, e.g., refer to thienyl (i.e., thiophenyl), furyl (i.e., furanyl), benzofuranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl, pyrrolyl (e.g., 2H-pyrrolyl), imidazolyl, pyrazolyl, pyridyl (i.e., pyridinyl; e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, furazanyl, 1H-tetrazolyl, or 2H-tetrazolyl. Unless defined otherwise, a "heteroaryl" preferably refers to a 5 to 8 membered; even more preferably, a 5 or 6 membered monocyclic ring comprising one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized. As used herein, the term "bicyclic heteroaryl" refers to an aromatic ring group, containing two, preferably anellated, rings, wherein one or both rings are aromatic. "Bicyclic heteroaryl" may, e.g., refer to benzo[b]thienyl, benzofuranyl, isobenzofuranyl, chromenyl, indolizinyl, isoindolyl, indolyl (e.g., 3H-indolyl), indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, cinnolinyl, 1,2-benzoisoxazol-3-yl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, coumarinyl, or chromonyl. Unless defined otherwise, a "bicyclic heteroaryl" preferably has 8 to 12 ring atoms, more preferably 9 or 10 ring atoms. It is to be understood that expressions such as "five or six-membered heterocyclic group" indicate a heterocyclic group having 5 or 6 atoms in the ring. Similarly, expressions such as "five to ten-membered heteroaryl group" indicate a heteroaryl group having 5 to 10 atoms in the one or two rings. Thus,"x-membered" in the context of cyclic groups indicates the number x of ring atoms in the one or more rings but does not imply any limitations as to the number of non-ring atoms, such as hydrogens which are typically present as substituents on the ring(s). The term “cycloalkyl” as used herein denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Cyclopropyl and cyclobutyl are preferred. The term “carbocyclic”, “carbocyclyl”, or “carbocycle” includes, unless otherwise indicated, in general a 3- to 10-membered monocyclic ring, preferably a 4- to 8-membered or a 3- to 6-membered or a 5- to 7-membered monocyclic ring, more preferably a 3-, 4-, 5- or 6- membered monocyclic ring, comprising 3 to 10, preferably 4 to 8 or 3 to 6 or 5 to 7, more preferably 3, 4, 5 or 6 carbon atoms. Unless otherwise indicated, the carbocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n + 2) rule is fulfilled. Also “aryls” are covered by the term “carbocycles”. The term “aryl” or “aromatic carbocycle” refers to aromatic carbocyclic rings based on carbon atoms as ring members, preferably 6-membered aromatic carbocyclic rings based on carbon atoms as ring members. A preferred example is phenyl. The term “carbocyclic” or “carbocyclyl”, unless otherwise indicated, may therefore cover inter alia cycloalkyl, cycloalkenyl, as well as phenyl. Preferably, the term “carbocyclic” or “carbocyclyl” covers phenyl and cycloalkyl, for example phenyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "carbobicyclic" or “carbobicyclyl” includes in general 5 to 14-membered, preferably 7- to 12-membered or 6- to 10-membered, more preferably 7- or 10-membered bicyclic rings comprising 5 to 14, preferably 7 to 12 or 6 to 10, more preferably 7 or 10 carbon atoms. The carbobicycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n + 2) rule is fulfilled. Preferably, the term “aromatic” in connection with the carbobicyclic ring means that both rings of the bicylic moiety are aromatic, so that, e.g., 8 π electrons are present in case of a 10-membered aromatic carbobicyclic ring. The term “carbobicylce” or “carbobicyclyl”, unless otherwise indicated, may therefore cover inter alia bicycloalkyl, bicycloalkenyl, as well as bicyclic aromatic groups, for example bicyclohexane (decalin), bicycloheptane (such as norbornane), bicyclooctane (such as bicyclo[2.2.2]octane, bicyclo[3.2.1]octane or bicyclo[4.2.0]octane), bicyclononane (such as bicyclo[3.3.1]nonane or bicyclo[4.3.0]nonane ), bicyclodecane (such as bicyclo[4.4.0]decane), bicycloundecane (such as bicyclo[3.3.3]undecane), norbornene, naphthalene and the like. The carbobicyclyl can be a bridged carbobicyclyl, a fused carbobicyclyl or a spiro-carbobicyclyl. Preferably, the carbobicyclyl is a spiro-carbobicyclyl. The term “carbocyclylalkyl” as used herein, refers to carbocyclyl as defined herein, which is bonded to the remainder of the molecule via an alkyl group having usually from 1 to 2 carbon atoms, preferably 1 carbon atom. Preferably, the term “carbocyclylalkyl” refers to phenylalkyl or cycloalkylalkyl, which refers to the corresponding groups being bonded to the remainder of the molecule via an alkyl group. Preferred examples of carbocyclylalkyl include benzyl (i.e. phenylmethyl), phenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl. The term “carbobicyclylalkyl” as used herein, refers to carbobicyclyl as defined herein, which is bonded to the remainder of the molecule via an alkyl group having usually from 1 to 2 carbon atoms, preferably 1 carbon atom. As used herein, the term “spiro-carbobicyclyl” or “spiro-carbobicyclic ring” refers, unless otherwise indicated, in general to a 7- to 10-membered, preferably 7- to 9-membered, more preferably 7- or 8-membered bicyclic ring comprising 7 to 10, preferably 7 to 9, more preferably 7 or 8 carbon atoms, wherein the two rings are connected via a single common carbon atom. The spiro-carbocyclic ring may be saturated or partially unsaturated, wherein saturated means that only single bonds are present and partially unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled. Preferably, the spiro-carbobicyclic ring is saturated. The term “heterocyclic” or “heterocyclyl” includes, unless otherwise indicated, in general a 3- to 10-membered, preferably a 4- to 8-membered or 5- to 7-membered, more preferably 5- or 6-membered, in particular 6-membered monocyclic ring. Unless indicated otherwise, the heterocycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n + 2) rule is fulfilled. The heterocycle typically comprises one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3, more preferably 1 or two, even more preferably 1, heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The remaining ring members are carbon atoms. In a preferred embodiment, the heterocycle is a saturated heterocycle, preferably a 4- to 6-membered saturated heterocycle comprising one or more, e.g. 1, 2, or 3, preferably 1 or 2, more preferably 1, heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. Examples of aromatic heterocycles are provided below in connection with the definition of “hetaryl”. “Hetaryls” or “heteroaryls” are covered by the term “heterocycles”. The saturated or partially or fully unsaturated heterocycles usually comprise 1, 2, 3, 4 or 5, preferably 1, 2 or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The skilled person is aware that S, SO or SO2is to be understood as follows: Further, a skilled person is aware that resonance structures of the oxidized forms may be possible. Saturated heterocycles include, unless otherwise indicated, in general 3- to 10- membered, preferably 4- to 8-membered or 5- to 7-membered, more preferably 4- to 6- membered monocyclic rings comprising 3 to 10, preferably 4 to 8 or 5 to 7, more preferably 4 to 6 atoms comprising at least one heteroatom, such as oxetane, azetidine, pyrrolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, tetrahydropyran, dioxane, morpholine or piperazine. The term “heterobicyclic” or “heterobicyclyl” includes, unless otherwise indicated, in general 6 to 14-membered, preferably 7- to 12-membered or 8- to 10-membered, more preferably 8- or 9-membered bicyclic rings. The heterobicycle may be saturated, partially or fully unsaturated, or aromatic, wherein saturated means that only single bonds are present, and partially or fully unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled, whereas aromatic means that the Hückel (4n + 2) rule is fulfilled. For being “aromatic”, it is sufficient if one of the two rings of the bicyclic moieties is aromatic, while the other is non-aromatic. The heterobicycle typically comprises one or more, e.g. 1, 2, 3, or 4, preferably 1, 2, or 3 heteroatoms selected from N, O and S as ring members, where S-atoms as ring members may be present as S, SO or SO2. The remaining ring members are carbon atoms. Examples of heterobicycles include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, quinolinyl, isoquinolinyl, purinyl, 1,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl, pyridoimidazolyl, triethylenediamine or quinuclidine and the like. The heterobicycle may be a fused heterobicyclyl, spiro heterobicyclyl, or bridged heterobicyclyl, preferably a spiro heterobicyclyl. The term "hetaryl" or “heteroaryl” or “aromatic heterocycle” or “aromatic heterocyclic ring” includes monocyclic 5- or 6-membered aromatic heterocycles comprising as ring members 1, 2, 3 or 4 heteroatoms selected from N, O and S, where S-atoms as ring members may be present as S, SO or SO2. Examples of 5- or 6-membered aromatic heterocycles include pyridyl (also referred to as pyridinyl), i.e.2-, 3-, or 4-pyridyl, pyrimidinyl, i.e.2-, 4- or 5- pyrimidinyl, pyrazinyl, pyridazinyl, i.e.3- or 4-pyridazinyl, thienyl, i.e.2- or 3-thienyl, furyl, i.e. 2-or 3-furyl, pyrrolyl, i.e.2- or 3-pyrrolyl, oxazolyl, i.e. 2-, 3- or 5-oxazolyl, isoxazolyl, i.e. 3-, 4- or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4- or 5-isothiazolyl, pyrazolyl, i.e.1-, 3-, 4- or 5-pyrazolyl, i.e.1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, e.g.2- or 5-[1,3,4]oxadiazolyl, 4- or 5-(1,2,3-oxadiazol)yl, 3- or 5-(1,2,4-oxadiazol)yl, 2- or 5-(1,3,4- thiadiazol)yl, thiadiazolyl, e.g. 2- or 5-(1,3,4-thiadiazol)yl, 4- or 5-(1,2,3-thiadiazol)yl, 3- or 5- (1,2,4-thiadiazol)yl, triazolyl, e.g. 1H-, 2H- or 3H-1,2,3-triazol-4-yl, 2H-triazol-3-yl, 1H-, 2H-, or 4H-1,2,4-triazolyl and tetrazolyl, i.e. 1H- or 2H-tetrazolyl. Unless otherwise indicated, the term “hetaryl” further covers “aromatic heterobicycles” as defined above. The term “heterocyclylalkyl” as used herein, refers to a heterocyclyl as defined herein, which is bonded to the remainder of the molecule via an alkyl group having usually from 1 to 2 carbon atoms, preferably 1 carbon atom. Examples of heterocyclylalkyl include pyridinylmethyl, pyrimidinylmethyl, pyrazolylmethyl, and piperidinylmethyl. The term “heterobicyclylalkyl” as used herein, refers to a heterocyclyl as defined herein, which is bonded to the remainder of the molecule via an alkyl group having usually from 1 to 2 carbon atoms, preferably 1 carbon atom. Examples of heterocyclylalkyl include pyridinylmethyl, pyrimidinylmethyl, pyrazolylmethyl, and piperidinylmethyl. As used herein, the term “spiro-heterobicyclyl” or “spiro-heterobicyclic ring” refers, unless otherwise indicated, in general to a 7- to 10-membered, preferably 7- to 9-membered, more preferably 7- or 8-membered bicyclic ring, wherein said ring group contains one or more, e.g., 1, 2, 3, or 4, preferably 1, 2, or 3, more preferably 1 or 2, even more preferably 1, ring heteroatoms independently selected from O, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and / or one or more N ring atoms (if present) may optionally be oxidized. The spiro-heterocyclic ring may be saturated or partially unsaturated, wherein saturated means that only single bonds are present and partially unsaturated means that one or more double bonds may be present in suitable positions, while the Hückel rule for aromaticity is not fulfilled. Preferably, the spiro- heterobicyclic ring is saturated. As used herein, terms such as "binding to at least one member of the E3 ligase complex" do not necessarily imply that the binding has to be directly to a moiety of the E3 ligase. Rather the compound may bind to a protein being part of the E3 ligase complex or a protein which interacts (before or after binding of the compound to the protein, optionally as part of a complex of proteins) with the E3 ligase complex. A skilled person will appreciate that the substituent groups comprised in the compounds of the present invention (in particular of formula (I)) may be attached to the remainder of the respective compound via a number of different positions of the corresponding specific substituent group. Unless defined otherwise, the preferred attachment positions for the various specific substituent groups are as illustrated in the examples. As used herein, unless explicitly indicated otherwise or contradicted by context, the terms "a", "an" and "the" are used interchangeably with "one or more" and "at least one". Thus, for example, a composition comprising "a" compound of the present invention (in particular of formula (I)) can be interpreted as referring to a composition comprising "one or more" compounds of the present invention. As used herein, the term "comprising" (or "comprise", "comprises", "contain", "contains", or "containing"), unless explicitly indicated otherwise or contradicted by context, has the meaning of "containing, inter alia", i.e., "containing, among further optional elements, …". In addition thereto, this term also includes the narrower meanings of "consisting essentially of" and "consisting of". For example, the term "A comprising B and C" has the meaning of "A containing, inter alia, B and C", wherein A may contain further optional elements (e.g., "A containing B, C and D" would also be encompassed), but this term also includes the meaning of "A consisting essentially of B and C" and the meaning of "A consisting of B and C" (i.e., no other components than B and C are comprised in A). Moreover, unless indicated otherwise, any reference to an industry standard, a pharmacopeia, or a manufacturer’s manual refers to the corresponding latest version that was available at the priority date (i.e., at the earliest filing date) of the present specification. The scope of the invention embraces all pharmaceutically acceptable salt forms of the compounds provided herein, particularly the compounds of the present invention (in particular of formula(I)), which may be formed, e.g., by protonation of an atom carrying an electron lone pair which is susceptible to protonation, such as an amino group, with an inorganic or organic acid, or as a salt of an acid group (such as a carboxylic acid group) with a physiologically acceptable cation. Exemplary base addition salts comprise, for example: alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts or tetrabutylammonium salts; and basic amino acid salts such as arginine salts, lysine salts, or histidine salts. Exemplary acid addition salts comprise, for example: mineral acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate salts (such as, e.g., sulfate or hydrogensulfate salts), nitrate salts, phosphate salts (such as, e.g., phosphate, hydrogenphosphate, or dihydrogenphosphate salts), carbonate salts, hydrogencarbonate salts, perchlorate salts, borate salts, or thiocyanate salts; organic acid salts such as acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, cyclopentanepropionate, decanoate, undecanoate, oleate, stearate, lactate, maleate, oxalate, fumarate, tartrate, malate, citrate, succinate, adipate, gluconate, glycolate, nicotinate, benzoate, salicylate, ascorbate, pamoate (embonate), camphorate, glucoheptanoate, or pivalate salts; sulfonate salts such as methanesulfonate (mesylate), ethanesulfonate (esylate), 2-hydroxyethanesulfonate (isethionate), benzenesulfonate (besylate), p-toluenesulfonate (tosylate), 2-naphthalenesulfonate (napsylate), 3-phenylsulfonate, or camphorsulfonate salts; glycerophosphate salts; and acidic amino acid salts such as aspartate or glutamate salts. Moreover, the scope of the invention embraces the compounds provided herein, particularly the compounds of the present invention (in particular of formulae (I) as hydrate. The term “hydrate” in connection with the compounds of formula (I) refers to a compound of formula (I), which contains water or its constituent elements (i.e. H and OH). Preferably, a hydrate of the compounds of formula (I) is a compound of formula (I), which incorporates water molecules in the crystalline structure but does not alter the chemical structure of formula (I). It is to be understood that such hydrates of the compounds provided herein, particularly the compounds of the present invention, also include hydrates of pharmaceutically acceptable salts of the corresponding compounds. Furthermore, the compounds provided herein, particularly the compounds of formulae (I), may exist in the form of different isomers, in particular stereoisomers (including, e.g., geometric isomers (or cis / trans isomers), enantiomers and diastereomers) or tautomers. All such isomers of the compounds provided herein are contemplated as being part of the present invention, either in admixture or in pure or substantially pure form. As for stereoisomers, the invention embraces the isolated optical isomers of the compounds according to the invention as well as any mixtures thereof (including, in particular, racemic mixtures / racemates). The racemates can be resolved by physical methods, such as, e.g., fractional crystallization, separation or crystallization of diastereomeric derivatives, or separation by chiral column chromatography. The individual optical isomers can also be obtained from the racemates via salt formation with an optically active acid followed by crystallization. The present invention further encompasses any tautomers of the compounds provided herein. The scope of the invention also embraces the compounds provided herein, particularly the compounds of formula (I), in which one or more atoms are replaced by a specific isotope of the corresponding atom. For example, the invention encompasses compounds of formula (I), in which one or more hydrogen atoms (or, e.g., all hydrogen atoms) are replaced by deuterium atoms (i.e.,2H; also referred to as "D"). Accordingly, the invention also embraces compounds of formulae (I), which are enriched in deuterium. Naturally occurring hydrogen is an isotopic mixture comprising about 99.98 mol-% hydrogen-1 (1H) and about 0.0156 mol-% deuterium (2H or D). The content of deuterium in one or more hydrogen positions in the compounds of formula (I), can be increased using deuteration techniques known in the art. For example, a compound of formula (I) or a reactant or precursor to be used in the synthesis of the compound of formula (I) can be subjected to an H / D exchange reaction using, e.g., heavy water (D2O). Further suitable deuteration techniques are described in: Atzrodt J et al., Bioorg Med Chem, 20(18), 5658-5667, 2012; William JS et al., Journal of Labelled Compounds and Radiopharmaceuticals, 53(11-12), 635-644, 2010; or Modvig A et al., J Org Chem, 79, 5861-5868, 2014. The content of deuterium can be determined, e.g., using mass spectrometry or NMR spectroscopy. Unless specifically indicated otherwise, it is preferred that the compound of formula (I), is not enriched in deuterium. Accordingly, unless indicated otherwise, the presence of naturally occurring hydrogen atoms or1H hydrogen atoms in the compounds of formula (I), is preferred. The present invention also embraces the compounds provided herein, particularly the compounds of formula (I), in which one or more atoms are replaced by a positron-emitting isotope of the corresponding atom, such as, e.g.,18F,11C,13N,15O,76Br,77Br,120I and / or124I. Such compounds can be used as tracers or imaging probes in positron emission tomography (PET). The invention thus includes (i) compounds of formula (I), in which one or more fluorine atoms (or, e.g., all fluorine atoms) are replaced by18F atoms, (ii) compounds of formula (I), (in which one or more carbon atoms (or, e.g., all carbon atoms) are replaced by11C atoms, (iii) compounds of formula (I), in which one or more nitrogen atoms (or, e.g., all nitrogen atoms) are replaced by13N atoms, (iv) compounds of formula (I), in which one or more oxygen atoms (or, e.g., all oxygen atoms) are replaced by15O atoms, (v) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine atoms) are replaced by76Br atoms, (vi) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine atoms) are replaced by77Br atoms, (vii) compounds of formula (I), in which one or more iodine atoms (or, e.g., all iodine atoms) are replaced by120I atoms, and (viii) compounds of formula (I), in which one or more iodine atoms (or, e.g., all iodine atoms) are replaced by124I atoms. In general, it is preferred that none of the atoms in the compounds of formula (I), are replaced by specific isotopes. The compounds provided herein, including in particular the compounds of formula (I), may be administered as compounds per se or may be formulated as medicaments. The medicaments / pharmaceutical compositions may optionally comprise one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and / or solubility enhancers. The pharmaceutical compositions may comprise one or more solubility enhancers, such as, e.g., poly(ethylene glycol), including poly(ethylene glycol) having a molecular weight in the range of about 200 to about 5,000 Da (e.g., PEG 200, PEG 300, PEG 400, or PEG 600), ethylene glycol, propylene glycol, glycerol, a non-ionic surfactant, tyloxapol, polysorbate 80, macrogol-15-hydroxystearate (e.g., Kolliphor®HS 15, CAS 70142-34-6), a phospholipid, lecithin, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, a cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxyethyl-γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, sulfobutylether-β- cyclodextrin, sulfobutylether-γ-cyclodextrin, glucosyl-α-cyclodextrin, glucosyl-β- cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, a carboxyalkyl thioether, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, a vinyl acetate copolymer, vinyl pyrrolidone, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or any combination thereof. The pharmaceutical compositions can be formulated by techniques known to the person skilled in the art, such as the techniques published in "Remington: The Science and Practice of Pharmacy", Pharmaceutical Press, 22ndedition. The pharmaceutical compositions can be formulated as dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardial, rectal, nasal, topical, aerosol or vaginal administration. Dosage forms for oral administration include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, troches, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewing tablets and effervescent tablets. Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions and powders and granules for reconstitution. Emulsions are a preferred dosage form for parenteral administration. Dosage forms for rectal and vaginal administration include suppositories and ovula. Dosage forms for nasal administration can be administered via inhalation and insufflation, for example by a metered inhaler. Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems. The compounds provided herein, particularly the compounds of formula (I), or the above described pharmaceutical compositions comprising such a compound may be administered to a subject by any convenient route of administration, whether systemically / peripherally or at the site of desired action, including but not limited to one or more of: oral (e.g., as a tablet, capsule, or as an ingestible solution), topical (e.g., transdermal, intranasal, ocular, buccal, and sublingual), parenteral (e.g., using injection techniques or infusion techniques, and including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal by, e.g., implant of a depot, for example, subcutaneously or intramuscularly), pulmonary (e.g., by inhalation or insufflation therapy using, e.g., an aerosol, e.g., through mouth or nose), gastrointestinal, intrauterine, intraocular, subcutaneous, ophthalmic (including intravitreal or intracameral), rectal, or vaginal administration. If said compounds or pharmaceutical compositions are administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracardially, intracranially, intramuscularly or subcutaneously administering the compounds or pharmaceutical compositions, and / or by using infusion techniques. For parenteral administration, the compounds are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. Said compounds or pharmaceutical compositions can also be administered orally in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications. The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, or high molecular weight polyethylene glycols. For aqueous suspensions and / or elixirs, the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and / or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof. Alternatively, said compounds or pharmaceutical compositions can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch. Said compounds or pharmaceutical compositions may also be administered by sustained release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include, e.g., polylactides (see, e.g., US 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly(2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP133988). Sustained-release pharmaceutical compositions also include liposomally entrapped compounds. Liposomes containing a compound of the present invention can be prepared by methods known in the art, such as, e.g., the methods described in any one of: DE3218121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. (USA) 77:4030-4034 (1980); EP0052322; EP0036676; EP088046; EP0143949; EP0142641; JP 83-118008; US 4,485,045; US 4,544,545; and EP0102324. Said compounds or pharmaceutical compositions may also be administered by the pulmonary route, rectal routes, or the ocular route. For ophthalmic use, they can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum. It is also envisaged to prepare dry powder formulations of the compounds provided herein, particularly the compounds of formula (I), for pulmonary administration, particularly inhalation. Such dry powders may be prepared by spray drying under conditions which result in a substantially amorphous glassy or a substantially crystalline bioactive powder. Accordingly, dry powders of the compounds of the present invention can be made according to the emulsification / spray drying process disclosed in WO 99 / 16419 or WO 01 / 85136. Spray drying of solution formulations of the compounds of the invention can be carried out, e.g., as described generally in the "Spray Drying Handbook", 5th ed., K. Masters, John Wiley & Sons, Inc., NY (1991), in WO 97 / 41833, or in WO 03 / 053411. For topical application to the skin, said compounds or pharmaceutical compositions can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, 2-octyldodecanol, benzyl alcohol and water. The present invention thus relates to the compounds or the pharmaceutical compositions provided herein, wherein the corresponding compound or pharmaceutical composition is to be administered by any one of: an oral route; topical route, including by transdermal, intranasal, ocular, buccal, or sublingual route; parenteral route using injection techniques or infusion techniques, including by subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, intrasternal, intraventricular, intraurethral, or intracranial route; pulmonary route, including by inhalation or insufflation therapy; gastrointestinal route; intrauterine route; intraocular route; subcutaneous route; ophthalmic route, including by intravitreal, or intracameral route; rectal route; or vaginal route. Particularly preferred routes of administration are oral administration or parenteral administration. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual subject undergoing therapy. A proposed, yet non-limiting dose of the compounds according to the invention for oral administration to a human (of approximately 70 kg body weight) may be 0.05 to 8000 mg, preferably 0.1 mg to 4000 mg, of the active ingredient per unit dose. The unit dose may be administered, e.g., 1 to 3 times per day. The unit dose may also be administered 1 to 7 times per week, e.g., with not more than one administration per day. A further exemplary dose of the compounds of formula (I) for oral administration to a human is 50 to 200 mg / kg bodyweight / day, particularly 100 mg / kg / day. It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient / subject as well as the severity of the condition to be treated. The precise dose and also the route of administration will ultimately be at the discretion of the attendant physician or veterinarian. The compounds provided herein, particularly the compound of formula (I) or a pharmaceutical composition comprising such a compound can be administered in monotherapy (e.g., without concomitantly administering any further therapeutic agents, or without concomitantly administering any further therapeutic agents against the same disease that is to be treated or prevented with the compound of formula (I),. However, the compound of formula (I), or a pharmaceutical composition comprising the compound of formula (I), can also be administered in combination with one or more further therapeutic agents. If the compound of formula (I) is used in combination with a second therapeutic agent active against the same disease or condition, the dose of each compound may differ from that when the corresponding compound is used alone, in particular, a lower dose of each compound may be used. The combination of the compound of formula (I) with one or more further therapeutic agents (such as, e.g., a BRD4 inhibitor, preferably a direct BRD4 inhibitor) may comprise the simultaneous / concomitant administration of the compound of formula (I) and the further therapeutic agent(s) (either in a single pharmaceutical formulation or in separate pharmaceutical formulations), or the sequential / separate administration of the compound of formula (I) and the further therapeutic agent(s). If administration is sequential, either the compound of formula (I) according to the invention or the one or more further therapeutic agents may be administered first. If administration is simultaneous, the one or more further therapeutic agents may be included in the same pharmaceutical formulation as the compound of formula (I) or they may be administered in one or more different (separate) pharmaceutical formulations. Preferably, the one or more further therapeutic agents to be administered in combination with a compound of the present invention are anticancer drugs. The anticancer drug(s) to be administered in combination with a compound of formula (I) according to the invention may, e.g., be selected from: a tumor angiogenesis inhibitor (e.g., a protease inhibitor, an epidermal growth factor receptor kinase inhibitor, or a vascular endothelial growth factor receptor kinase inhibitor); a cytotoxic drug (e.g., an antimetabolite, such as purine and pyrimidine analog antimetabolites); an antimitotic agent (e.g., a microtubule stabilizing drug or an antimitotic alkaloid); a platinum coordination complex; an anti-tumor antibiotic; an alkylating agent (e.g., a nitrogen mustard or a nitrosourea); an endocrine agent (e.g., an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analog); or a compound that targets an enzyme or receptor that is overexpressed and / or otherwise involved in a specific metabolic pathway that is misregulated in the tumor cell (e.g., ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors (such as serine, threonine and tyrosine kinase inhibitors, e.g., Abelson protein tyrosine kinase inhibitors) and the various growth factors, their receptors and corresponding kinase inhibitors (such as epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors)); methionine, aminopeptidase inhibitors, proteasome inhibitors, cyclooxygenase inhibitors (e.g., cyclooxygenase-1 or cyclooxygenase-2 inhibitors), topoisomerase inhibitors (e.g., topoisomerase I inhibitors or topoisomerase II inhibitors), poly ADP ribose polymerase inhibitors (PARP inhibitors), and epidermal growth factor receptor (EGFR) inhibitors / antagonists. An alkylating agent which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a nitrogen mustard (such as cyclophosphamide, mechlorethamine (chlormethine), uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, or trofosfamide), a nitrosourea (such as carmustine, streptozocin, fotemustine, lomustine, nimustine, prednimustine, ranimustine, or semustine), an alkyl sulfonate (such as busulfan, mannosulfan, or treosulfan), an aziridine (such as hexamethylmelamine (altretamine), triethylenemelamine, ThioTEPA (N,N'N'- triethylenethiophosphoramide), carboquone, or triaziquone), a hydrazine (such as procarbazine), a triazene (such as dacarbazine), or an imidazotetrazine (such as temozolomide). A platinum coordination complex which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, or triplatin tetranitrate. A cytotoxic drug which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, an antimetabolite, including folic acid analogue antimetabolites (such as aminopterin, methotrexate, pemetrexed, or raltitrexed), purine analogue antimetabolites (such as cladribine, clofarabine, fludarabine, 6- mercaptopurine (including its prodrug form azathioprine), pentostatin, or 6-thioguanine), and pyrimidine analogue antimetabolites (such as cytarabine, decitabine, 5-fluorouracil (including its prodrug forms capecitabine and tegafur), floxuridine, gemcitabine, enocitabine, or sapacitabine). An antimitotic agent which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a taxane (such as docetaxel, larotaxel, ortataxel, paclitaxel / taxol, tesetaxel, or nab-paclitaxel (e.g., Abraxane®)), a Vinca alkaloid (such as vinblastine, vincristine, vinflunine, vindesine, or vinorelbine), an epothilone (such as epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, or epothilone F) or an epothilone B analogue (such as ixabepilone / azaepothilone B). An anti-tumor antibiotic which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, an anthracycline (such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, or zorubicin), an anthracenedione (such as mitoxantrone, or pixantrone) or an anti-tumor antibiotic isolated from Streptomyces (such as actinomycin (including actinomycin D), bleomycin, mitomycin (including mitomycin C), or plicamycin). A tyrosine kinase inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, axitinib, bosutinib, cediranib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, semaxanib, sorafenib, sunitinib, axitinib, nintedanib, ponatinib, or vandetanib. A topoisomerase inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a topoisomerase I inhibitor (such as irinotecan, topotecan, camptothecin, belotecan, rubitecan, or lamellarin D) or a topoisomerase II inhibitor (such as amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin). A PARP inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, BMN-673, olaparib, rucaparib, veliparib, CEP 9722, MK 4827, BGB-290, or 3-aminobenzamide. An EGFR inhibitor / antagonist which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, gefitinib, erlotinib, lapatinib, afatinib, neratinib, ABT-414, dacomitinib, AV-412, PD 153035, vandetanib, PKI-166, pelitinib, canertinib, icotinib, poziotinib, BMS-690514, CUDC-101, AP26113, XL647, cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab. Further anticancer drugs may also be used in combination with a compound of the present invention. The anticancer drugs may comprise biological or chemical molecules, like TNF-related apoptosis-inducing ligand (TRAIL), tamoxifen, amsacrine, bexarotene, estramustine, irofulven, trabectedin, cetuximab, panitumumab, tositumomab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, alvocidib, seliciclib, aminolevulinic acid, methyl aminolevulinate, efaproxiral, porfimer sodium, talaporfin, temoporfin, verteporfin, alitretinoin, tretinoin, anagrelide, arsenic trioxide, atrasentan, bortezomib, carmofur, celecoxib, demecolcine, elesclomol, elsamitrucin, etoglucid, lonidamine, lucanthone, masoprocol, mitobronitol, mitoguazone, mitotane, oblimersen, omacetaxine, sitimagene, ceradenovec, tegafur, testolactone, tiazofurine, tipifarnib, vorinostat, or iniparib. Also biological drugs, like antibodies, antibody fragments, antibody constructs (for example, single-chain constructs), and / or modified antibodies (like CDR-grafted antibodies, humanized antibodies, "full humanized" antibodies, etc.) directed against cancer or tumor markers / factors / cytokines involved in proliferative diseases can be employed in cotherapy approaches with the compounds of the invention. Examples of such biological molecules are anti-HER2 antibodies (e.g. trastuzumab, Herceptin®), anti-CD20 antibodies (e.g. Rituximab, Rituxan®, MabThera®, Reditux®), anti-CD19 / CD3 constructs (see, e.g., EP1071752) and anti-TNF antibodies (see, e.g., Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003. 3(3):323-328). Further antibodies, antibody fragments, antibody constructs and / or modified antibodies to be used in cotherapy approaches with the compounds of the invention can be found, e.g., in: Taylor PC. Curr Opin Pharmacol. 2003. 3(3):323-328; or Roxana A. Maedica.2006.1(1):63-65. An anticancer drug which can be used in combination with a compound of the present invention may, in particular, be an immunooncology therapeutic (such as an antibody (e.g., a monoclonal antibody or a polyclonal antibody), an antibody fragment, an antibody construct (e.g., a single-chain construct), or a modified antibody (e.g., a CDR-grafted antibody, a humanized antibody, or a "full humanized" antibody) targeting any one of CTLA-4, PD-1 / PD-L1, TIM3, LAG3, OX4, CSF1R, IDO, or CD40. Such immunooncology therapeutics include, e.g., an anti-CTLA-4 antibody (particularly an antagonistic or pathway-blocking anti-CTLA-4 antibody; e.g., ipilimumab or tremelimumab), an anti-PD-1 antibody (particularly an antagonistic or pathway-blocking anti-PD-1 antibody; e.g., nivolumab (BMS- 936558), pembrolizumab (MK-3475), pidilizumab (CT-011), AMP-224, or APE02058), an anti-PD-L1 antibody (particularly a pathway-blocking anti-PD-L1 antibody; e.g., BMS- 936559, MEDI4736, MPDL3280A (RG7446), MDX-1105, or MEDI6469), an anti-TIM3 antibody (particularly a pathway-blocking anti-TIM3 antibody), an anti-LAG3 antibody (particularly an antagonistic or pathway-blocking anti-LAG3 antibody; e.g., BMS-986016, IMP701, or IMP731), an anti-OX4 antibody (particularly an agonistic anti-OX4 antibody; e.g., MEDI0562), an anti-CSF1R antibody (particularly a pathway-blocking anti-CSF1R antibody; e.g., IMC-CS4 or RG7155), an anti-IDO antibody (particularly a pathway-blocking anti-IDO antibody), or an anti-CD40 antibody (particularly an agonistic anti-CD40 antibody; e.g., CP- 870,893 or Chi Lob 7 / 4). Further immunooncology therapeutics are known in the art and are described, e.g., in: Kyi C et al., FEBS Lett, 2014, 588(2):368-76; Intlekofer AM et al., J Leukoc Biol, 2013, 94(1):25-39; Callahan MK et al., J Leukoc Biol, 2013, 94(1):41-53; Ngiow SF et al., Cancer Res, 2011, 71(21):6567-71; and Blattman JN et al., Science, 2004, 305(5681):200-5. A BRD4 inhibitor (preferably a direct BRD4 inhibitor) may also be used as a further therapeutic agent in combination with the compound of formula (I). The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation. The individual components of such combinations may be administered either sequentially or simultaneously / concomitantly in separate or combined pharmaceutical formulations by any convenient route. When administration is sequential, either the compound of the present invention (particularly the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof) or the further therapeutic agent(s) may be administered first. When administration is simultaneous, the combination may be administered either in the same pharmaceutical composition or in different pharmaceutical compositions. When combined in the same formulation, it will be appreciated that the two or more compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately, they may be provided in any convenient formulation. The compounds provided herein, particularly the compounds of formula (I) can also be administered in combination with physical therapy, such as radiotherapy. Radiotherapy may commence before, after, or simultaneously with administration of the compounds of the invention. For example, radiotherapy may commence 1-10 minutes, 1-10 hours or 24-72 hours after administration of the compounds. Yet, these time frames are not to be construed as limiting. The subject is exposed to radiation, preferably gamma radiation, whereby the radiation may be provided in a single dose or in multiple doses that are administered over several hours, days and / or weeks. Gamma radiation may be delivered according to standard radiotherapeutic protocols using standard dosages and regimens. The present invention thus relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, for use in the treatment or prevention of cancer, wherein the compound or the pharmaceutical composition is to be administered in combination with one or more anticancer drugs and / or in combination with radiotherapy. Yet, the compounds of formula (I) can also be used in monotherapy, particularly in the monotherapeutic treatment or prevention of cancer (i.e., without administering any other anticancer agents until the treatment with the compound(s) of formula (I) is terminated). Accordingly, the invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, for use in the monotherapeutic treatment or prevention of cancer. The subject or patient to be treated in accordance with the present invention may be an animal (e.g., a non-human animal), a vertebrate animal, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, or a mouse), a canine (e.g., a dog), a feline (e.g., a cat), a porcine (e.g., a pig), an equine (e.g., a horse), a primate or a simian (e.g., a monkey or an ape, such as a marmoset, a baboon, a gorilla, a chimpanzee, an orangutan, or a gibbon), or a human. In accordance with the present invention, it is envisaged that animals are to be treated which are economically, agronomically or scientifically important. Scientifically important organisms include, but are not limited to, mice, rats, and rabbits. Lower organisms such as, e.g., fruit flies like Drosophila melagonaster and nematodes like Caenorhabditis elegans may also be used in scientific approaches. Non-limiting examples of agronomically important animals are sheep, cattle and pigs, while, for example, cats and dogs may be considered as economically important animals. Preferably, the subject / patient is a mammal. More preferably, the subject / patient is a human or a non-human mammal (such as, e.g., a guinea pig, a hamster, a rat, a mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a marmoset, a baboon, a gorilla, a chimpanzee, an orangutan, a gibbon, a sheep, cattle, or a pig). Most preferably, the subject / patient is a human. The term "prevention" of a disorder or disease as used herein (e.g., "prevention" of cancer) is also well known in the art. For example, a patient / subject suspected of being prone to suffer from a disorder or disease may particularly benefit from a prevention of the disorder or disease. The subject / patient may have a susceptibility or predisposition for a disorder or disease, including but not limited to hereditary predisposition. Such a predisposition can be determined by standard methods or assays, using, e.g., genetic markers or phenotypic indicators. It is to be understood that a disorder or disease to be prevented in accordance with the present invention has not been diagnosed or cannot be diagnosed in the patient / subject (for example, the patient / subject does not show any clinical or pathological symptoms). Thus, the term "prevention" comprises the use of a compound of the present invention before any clinical and / or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician. Cyclin dependent kinases (CDKs) are a family of Ser / Thr kinases that integrate various signal transduction pathways and play a key role in several key cellular processes. CDK12 and its orthologue CDK13 belong to the class of ‘transcriptional’ CDKs. Transcription of protein-coding genes is controlled by RNA Polymerase II. Phosphorylation of residues in its C-terminal domain (CTD) orchestrate the production of mature mRNA transcript. Phosphorylation of Ser2, which promotes elongation of RNA Pol II through the gene body, is a key mechanism of CDK12 transcriptional regulation (Genes & Development 2010, 24:2303-2316). CDK12 and CDK13 associate with their obligate partner Cyclin K to regulate multiple cellular processes, including transcriptional elongation, pre-mRNA splicing, and cell cycle progression. Additionally, CDK12 knockdown has been associated with downregulation of genes involved in homologous recombination and the DNA damage response (DDR) (Genes & Development 2011, 25:2158-2172). Hence, maintenance of genomic stability appears to be a key role of this protein. CDK12 is often dysregulated in human cancers and is an attractive therapeutic target. Mutation of CDK12 in serious ovarian carcinoma is associated with decreased expression of DDR genes such as BRCA1, FANCI, ATM, ATR or FANCD2 and increased sensitivity to PARP inhibitors. (Cancer Res, 2016, 76(7) 1182; Nucleic Acids Research, 2015, Vol.43, 2575-2589). The frequency and distribution of CDK12 protein expression was assessed by immunohistochemistry (IHC) in independent cohorts of breast cancer and this was correlated with outcome and genomic status. It was found that 21% of primary unselected breast cancers were CDK12 high, and 10.5% were absent. CDK12 overexpression in breast cancer cells has been demonstrated to regulate splicing of pre-mRNA involved in DDR and tumorigenesis. (Nucleic Acids Res., 2017, Jun 20;45(11 ):6698-6716). Disruption of Cyclin- Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1 / 2 inhibitors. Interestingly, absence of CDK12 protein was associated with reduced expression of a number of DDR proteins including ATR, Ku70 / Ku80, PARP1, DNA-PK, and γΗ2ΑΧ, suggesting a novel mechanism of CDK12- associated DDR dysregulation in breast cancer. This may have important therapeutic implications, particularly for triple-negative breast cancers. (Molecular Cancer Therapeutics (2018), 17(1), 306-315). Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Amplification or overexpression of HER2 occurs in approximately 15–30% of breast cancers and 10–30% of gastric / gastroesophageal cancers and serves as a prognostic and predictive biomarker. HER2 overexpression has also been seen in other cancers like ovary, endometrium, bladder, lung, colon, and head and neck. The introduction of HER2 directed therapies has dramatically influenced the outcome of patients with HER2 positive breast and gastric / gastroesophageal cancers (Mol Biol Int.2014; 2014: 852748). In breast cancer, HER2 is a part of the frequently amplified and overexpressed 17q12-q21 locus. 17q12-q21 amplicon commonly contains several neighboring genes including MED1, GRB7, MSL1, CASC3 and TOP2A. The HER2 amplicon also contains the CDK12 gene in 71% of cases (Cell Division, Volume 12, Article number: 7 (2017)). High CDK12 expression caused by concurrent amplification of CDK12 and HER2 in breast cancer patients is associated with disease recurrence and poor survival (EMBO Rep (2019)20:e48058). The design of selective ATP-competitive kinase inhibitors is challenging, due to the similarity of the ATP binding sites, as well as difficulties in overcoming the overwhelmingly high intracellular concentrations of ATP. To date, all CDK12 inhibitors in clinical trials are pan-CDK inhibitors (Dinaciclib). As an alternative to classical competitive inhibition, degradation of the target of interest is therefore an attractive alternative, especially if such degraders can overcome common problems of ATP competitive kinase inhibitors such as poor permeability, low oral availability, poor CNS penetration, and high levels of P-gp and BCRP1 mediated efflux. The present invention relates to compounds that cause degradation of Cyclin K via a “molecular glue” mechanism and consequently selective inactivation of CDK12 and CDK13. This is achieved via stabilization of an interaction between a CDK12 / Cyclin K complex and a Cullin-RING E3 ligase (CRL). CRLs are multi-subunit complexes composed of a Cullin scaffold (e.g. CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5, CUL7, CUL9) and a substrate receptor (SR) conferring target specificity to the complex (e.g. CRBN, VHL, DCAF15) recruited via an adaptor subunit (e.g. DDB1, SKP1, ELOB / C). A target protein presented by the SR is tagged for proteasomal degradation via transfer of ubiquitin by E2 enzymes recruited to the CRL. For the present invention, the CDK12 / Cyclin K interacts with a CRL complex comprises CUL4A or CUL4B and DDB1. CDK12 directly binds to DDB1 and acts as a surrogate SR to expose Cyclin K for ubiquitination. Cyclin K degradation is a property that has been described for some, but not all inhibitors of CDK12. Interaction between CDK12 and DDB1 is driven, in part, due to interactions of the inhibitor with DDB1. Therefore, only CDK12 inhibitors that simultaneously occupy the kinase active site and fill the hydrophobic pocket of DDB1 can promote Cyclin K degradation. For example, the pan-CDK inhibitor CR8 was found to cause Cyclin K degradation by this mechanism, whereas the CDK12 selective covalent inhibitor THZ-531 did not cause cyclin K degradation. However, prediction of Cyclin K degradation properties of a CDK12 inhibitor or design of a Cyclin K degrader are not obvious. Consequently, the Cyclin K degraders reported in the literature have been discovered serendipitously. It is believed that CDK12 and CDK13 share a largely overlapping target space (Liang et al, 2015) and therefore CDK13 is able to compensate loss of CDK12 enzymatic activity. Cyclin K is the obligate partner for both CDK12 and CDK13 and is needed for their activity. Cyclin K degraders will therefore cause impaired activity of both kinases, potentially circumventing such compensatory signaling. Restoration of CDK12 activity upon treatment with Cyclin K degraders requires the re- synthesis of Cyclin K. Cyclin K is a relatively long-lived protein with a reported half-life > 12 hours. Hence, the compounds object of the present invention are expected to have a therapeutic effect in cells and tumors that extends well beyond exposure to the molecule. This favorable disconnect between pharmacokinetics and pharmacodynamics can be exploited to further optimize the selectivity profile of these molecules and reduce the dosing schedule. EXAMPLES EXAMPLE 1: Synthesis List of abbreviations: abbreviation explanation µM micromolar ACN acetonitrile DCM dichloromethane DIEA diisopropylethylamine DIPA Diisoproylamine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EA ethyl acetate ESI / ES electron spray ionization FA formic acid HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium Hex Hexanes HPLC high performance liquid chromatography IPA Isopropanol LC liquid chromatography LCMS liquid chromatography coupled mass spectrometry LDA lithium diisopropyl amide mM Millimolar MTBE Methyl tert-Butyl Ether NCS N-chlorosuccinimide NMR Nuclear Magnetic Resonance PE petroleum ether T3P Propanephosphonic acid anhydride TEA Triethyl amine TFA triflouro acetic acid THF tetrahydrofuran Instrument specifications: NMR: Bruker AVANCE DRX 500 Varian UNITYplus 400 Proton nuclear magnetic resonance spectra (NMR) were recorded at 400 MHz or 500 MHz. Chemical shifts (δ) are given in parts per million (ppm) and are listed upfield with tetramethylsilane as a reference. Peaks are described as singlets (s), doublets (d), triplets (t), quartets (q), quintets (quint) multiplets (m) and broad (br.). LCMS: Shimadzu LCMS-2020 Series LC / MSD system with PDA SPD-M40 and Shimadzu LCMS- 2020 mass-spectrometer Shimadzu LCMS-2020 Series LC / MSD system with PDA\ELSD SPD-M40 / LT Ⅲ and Shimadzu LCMS-2020 mass-spectrometer. Shimadzu LCMS-2020 Series LC / MSD system with PDA\ELSD SPD-M40 / 3300HP and Shimadzu LCMS-2020 mass-spectrometer. Shimadzu LCMS-2020 Series LC / MSD system with PDA SPD-M20A and Shimadzu LCMS- 2020 mass-spectrometer. Shimadzu LCMS-2020 Series LC / MSD system with PDA\ELSD SPD-M20A / 3300HP and Shimadzu LCMS-2020 mass-spectrometer. Method A: Column: EVO C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 1.20 min - 95% B, 1.70 min: 95% B, 1.75 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method B: Column: Express C183.0 x 30 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 0.80 min - 95% B, 1.20 min: 95% B, 1.25 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 50-1500 PDA: 254 nm, 220 nm, 200 nm Method C: Column: EVO C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 2.00 min - 70% B, 2.20 min - 95% B, 2.60 min: 95% B, 2.75 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method D: Column: Express C183.0 x 30 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 2.10 min - 95% B, 2.60 min: 95% B, 2.75 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method E: Column: HPH C183.0 x 50 mm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN containing 0.1% FA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.20 min - 100% B, 1.75 min: 100% B, 1.85 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method F: Column: EC C183.0 x 30 mm Temperature: 40 °C Mobile phase A: water containing 0.05% TFA Mobile phase B: MeCN containing 0.05% TFA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 0.80 min - 100% B, 1.20 min: 100% B, 1.25 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method G: Column: HPH C1850 x 3.0 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 2.10 min - 95% B, 2.60 min: 95% B, 2.75 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method H: Column: Poroshell HPH C1850 x 3.0 mm, 4.0 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 2 min - 70% B, 2.2 min - 95% B, 2.7 min: 95% B, 2.8 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method I: Column: Polar C183.0 x 30 mm, 2.1 μm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.20min - 100% B, 1.80 min: 100% B, 1.82 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method J: Column: HPH C183.0 x 50 mm, 2.7 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 1.20min - 95% B, 1.70 min: 95% B, 1.75 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method K: Column: HPH C183.0 x 50 mm, 2.7 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 2.00min - 70% B, 2.20 min: 95% B, 2.70 min: 95% B,2.80min:10%B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method L: Column: Ascentis C183.0 x 30 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 0.05% TFA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.20 min - 100% B, 1.80 min: 100% B, 1.82 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method M: Column: EVO C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 0.1%FA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.20 min - 100% B, 1.80 min – 100% B, 1.82 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method N: Column: Polar-C182.1 x 30 mm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 30% B, 1.80 min - 70% B, 2.00 min: 100% B, 2.70 min: 100% B, 2.80 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method O: Column: HALO C183.0 x 30 mm, 2.0um Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN containing 0.1% FA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.80 min - 70% B, 2.00 min: 100% B, 2.70 min: 100% B, 2.80 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method P: Column: Shim-pack Scepter C183.0 x 33 mm, 2.7 μm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN containing 0.1% FA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 1.2 min - 100% B, 1.80 min: 100% B, 1.82 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method Q: Column: HALO C183.0 x 30 mm, 2.0 μm Temperature: 40 °C Mobile phase A: water containing 0.1% FA Mobile phase B: MeCN containing 0.1% FA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 0.70 min - 100% B,1.10 min - 100% B, 1.11 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method R: Column: EVO-C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.8 min - 95% B, 1.20 min - 95% B, 1.25 min- 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method S: Column: HPH C183.0 x 50 mm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B, 1.20min - 95% B, 1.70 min: 95% B, 1.75 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method T: Column: Ascentis ExpresC183.0 x 30 mm, 2.7 μm Temperature: 40 °C Mobile phase A: water containing 0.05% TFA Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 1.20 min - 100% B, 1.80 min: 100% B, 1.82 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method U: Column: Poroshell HPH C1850 x 3.0 mm, 4.0 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 2 min - 95% B, 2.6 min - 95% B, 2.7 min: 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method V; Column: EVO-C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: Water / 0.04%NH3H2O Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 10% B 2.3 min - 95% B, 2.65 min - 95% B, 2.70 min- 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method W: Column: ShimNex HE C18-AQ 3.0 x 30 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 0.05% TFA Mobile phase B: MeCN containing 0.05% TFA Flow rate: 1.5 mL / min Elution Gradient: 0.01 min - 5% B, 2.0 min - 60% B, 2.20 min: 100% B, 2.60 min: 100% B 2.74 min: 5% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-900 PDA: 254 nm, 220 nm, 200 nm Method X: Column: Kinetex EVO-C183.0 x 50 mm, 2.6 μm Temperature: 40 °C Mobile phase A: water containing 5 mM NH4HCO3 Mobile phase B: MeCN Flow rate: 1.5 mL / min Elution Gradient: 2.0 min - 60% B, 2.20 min - 95% B, 2.60 min- 95% B, 2.70 min- 10% B Injection volume: 0.5pl Ionization mode: Electrospray ionization (ESI) Scan range: m / z 90-1500 PDA: 254 nm, 220 nm, 200 nm Method Y: Column: Agilent Poroshell 120 SB-C184.6x30mm 2.7 µm Column Temperature: 60°C Mobile phase: А – water, В – acetonitrile Flow rate: 3 ml / min Gradient: 0.01 min –1% B, 1.5 min – 100% B, 1.73 min – 100% B, MS Ionization mode: Electrospray ionization (ESI) MS Scan range: 83 – 600 m / z UV detection: 215 nm, 254nm, 280 nm Synthetic procedures

[0032] [1-(3-chlorophenyl)-1H-pyrazol-3-yl]methanol To a stirred solution of 1-(3-chlorophenyl)-1H-pyrazole-3-carboxylic acid (5.2 g, 23.42 mmol) in THF (100 mL) was added lithium aluminium hydride (1.19 g, 35.13 mmol) at 0°C. The reaction mixture was stirred at room temperature for 12 h. The mixture was cooled to 0°C and quenched with sat NaOH solution and filtered through celite. The residue was washed with ethyl acetate (100 mL) and the filtrate was dried over anhydrous Na2SO4and concentrated under reduced pressure to afford [1-(3-chlorophenyl)-1H-pyrazol-3- yl]methanol (3.7 g, 75.96% yield) as a yellow solid. The compound was used for the next step without purification. 3-(chloromethyl)-1-(3-chlorophenyl)-1H-pyrazole [1-(3-Chlorophenyl)-1H-pyrazol-3-yl]methanol (3.7 g, 17.79 mmol) in dichloromethane (50 mL) was treated with thionyl chloride (2.52 g, 21.34 mmol, 1.53 ml) and the mixture stirred at room temperature for 12 h. The resulting solution was evaporated to afford 3- (chloromethyl)-1-(3-chlorophenyl)-1H-pyrazole (4.0g, 100% yield). 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetonitrile To a solution of 3-(chloromethyl)-1-(3-chlorophenyl)-1H-pyrazole (4.0 g, 17.7 mmol) in DMSO (50 mL) was added sodium cyanide (1.73 g, 35.4 mmol) at 25°C. After stirring at 25°C for 12 h, the mixture was treated with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetonitrile (3.8 g, crude). 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetic acid To a suspension of 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetonitrile (3.8 g, 17.51 mmol) in EtOH / H2O (20 mL / 10 mL) was added sodium hydroxide (1.75 g, 43.77 mmol). The mixture was refluxed for 4 h. After the completion of the reaction, it was concentrated under reduced pressure to obtain 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetic acid (3.3 g, crude), which was used at the next step directly without further purification. methyl 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]acetate 2-[1-(3-Chlorophenyl)-1H-pyrazol-3-yl]acetic acid (3.3 g, 14.0 mmol) and thionyl chloride (2.48 g, 21.0 mmol, 1.51 ml) were refluxed in MeOH (100 mL) for 8 h. The solvent was removed under reduced pressure and aqueous solution of NaHCO3(50 mL) was added. The aqueous layer was extracted with methyl tert-butyl ether (2 x 75 mL). The combined organic layers were separated, dried with Na2SO4and concentrated in vacuo to give methyl 2-[1-(3- chlorophenyl)-1H-pyrazol-3-yl]acetate (3.8 g, crude). methyl 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanoate In a three-necked flask equipped with a tube for introducing an inert gas and a low- temperature thermometer was placed a solution of bis(propan-2-yl)amine (1.48 g, 14.59 mmol, 2.06 ml) in anhydrous THF (25 mL) and it was cooled to −78°C under argon. N- Butyl lithium (973.86 mg, 15.2 mmol, 6.61 ml) was added slowly over 10 minutes. The mixture was stirred for 30 min at 0°C and then it was cooled to −20°C. Methyl 2-[1-(3- chlorophenyl)-1H-pyrazol-3-yl]acetate (3.8 g, 15.2 mmol) in THF (25 mL) and followed by iodomethane (2.07 g, 14.59 mmol, 910.0 µl, 1.2 equiv.) were added. The reaction mixture was stirred at room temperature overnight under argon atmosphere. The solvent was removed under reduced pressure and aqueous solution of NaHCO3(20 mL) was added. The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were separated, dried with Na2SO4and concentrated in vacuo to give crude product. This was purified with flash chromatography to afford methyl 2-[1-(3-chlorophenyl)-1H-pyrazol- 3-yl]propanoate (3.3 g, 83.0% yield). 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanoic acid To a suspension of methyl 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanoate (3.3 g, 12.5 mmol) in THF / H2O (20 mL / 5 mL) was added sodium hydroxide (749.74 mg, 18.75 mmol). The mixture was stirred at room temperature overnight. After the completion of the reaction, the solvents were removed in vacuo and HCl was added. The precipitate was filtered and dried to obtain 2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanoic acid (2.0 g, crude), which was used at the next step directly without further purification. N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanamide 2-[1-(3-Chlorophenyl)-1H-pyrazol-3-yl]propanoic acid (400.0 mg, 1.6 mmol) was dissolved in DMF (5 mL) and then 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate (912.25 mg, 2.4 mmol) and ethylbis(propan-2- yl)amine (516.62 mg, 4.0 mmol, 700.0 µl) were added to the solution. The solution was stirred for 30 min and then 3-tert-butyl-1H-pyrazol-5-amine (222.58 mg, 1.6 mmol) was added. The resulting mixture was stirred at 70°C for 16 h. After confirmation of completion of the reaction by LCMS, the crude product was purified by HPLC (0-2-6 min 55-65-75% H2O / MeOH, flow 30 mL / min ((loading pump 4 mL MeOH); column: Chromatorex C18 SMB100-5T 100*19 mm, 5 microM) to afford N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[1-(3- chlorophenyl)-1H-pyrazol-3-yl]propanamide (130.0 mg, 21.90% yield). N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanamide, Enantiomer 1 and Enantiomer 2. N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]propanamide was subjected to chiral HPLC using the following conditions Column: CHIRALPAK IA (250 x 21 mm, 5 mkm), Mobile Phase: Hexane (0.2%DEA):IPA:MeOH, 50:25:25, Flow Rate: 12 mL / min. This afforded: • First eluting enantiomer / enantiomer 1, Compound 1, (66.88 mg, 51.45% yield) LCMS [method Y] Calculated 371.86. Found [M+H]+: 372.0; Rt = 3.515 min • Second eluting enantiomer / enantiomer 2, Compound 2, (58.85 mg, 45.25% yield LCMS [method Y] Calculated: 371.86. Found [M+H]+: 372.0; Rt = 3.515 min. Synthesis of Compound 3 5-cyclopropyl-1,3-thiazol-2-amine 2-Cyclopropylacetaldehyde (10.0 g, 118.97 mmol), aminoformonitrile (6.0 g, 142.76 mmol), morpholine (10.36 g, 118.97 mmol, 10.4 ml) and sulfanylidene (3.8 g, 118.97 mmol) were refluxed for 6 h in EtOH (150 mL). After confirmation of completion of the reaction by LCMS, the reaction mixture was filtered and evaporated under reduced pressure. The crude product was acidified with 1 M HCl (75 mL) and washed with MTBE (2x 50 ml). Then NaOH (1 M aq. solution) was added, and it was extracted with CHCl3(2 x 100 mL). The residue was recrystallized with i-PrOH / MTBE (100 mL) and filtered to give 5-cyclopropyl-1,3- thiazol-2-amine (0.21 g, crude). N-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetamide 2-[1-(Pyridin-2-yl)-1H-pyrazol-3-yl]acetic acid (300.0 mg, 1.48 mmol) was dissolved in DMF (5 mL) and then 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (842.8 mg, 2.22 mmol) and N-Ethyl-N-(propan-2-yl)propan-2- amine (477.29 mg, 3.7 mmol, 640.0 µl) were added to the resulting solution. After stirring for 30 min 5-cyclopropyl-1,3-thiazol-2-amine (207.01 mg, 1.48 mmol) was added. The resulting mixture was stirred at 60°C for 16 h. After confirmation of completion of the reaction by LCMS, the crude product was subjected to HPLC (0-2-6 min 17-25-50% H2O+FA / MeCN, 30 ml / min (loading pump 4 ml ACN); column: Chromatorex 100*19 mm, 5 microM). After HPLC N-(5-cyclopropyl-1,3-thiazol-2-yl)-2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetamide, Compound 3, (42.5 mg, 130.61 µmol, 8.8% yield) was obtained. 1H NMR (DMSO-d6, 500 MHz) δ (ppm): 0.61 (m, 2H), 0.90 (m, 2H), 1.99 (m, 1H), 3.81 (s, 2H), 6.48 (d, 1H), 7.10 (s, 1H), 7.30 (m, 1H), 7.80 (m, 1H), 7.95 (m, 1H), 8.42 (d, 1H), 8.53 (d, 1H), 12.18 (s, 1H). LCMS [Methos Y] Calculated: 325.11. Found [M+H]+: 326.0; Rt = 1.059 min. ethyl 2-(1H-pyrazol-3-yl)acetate To a solution of 2-(1H-pyrazol-5-yl)acetic acid hydrochloride (1.0 g, 6.17 mmol) in ethanol (10 mL) sulfuric acid (60.5 mg, 617.51 µmol) was added. The resulting mixture was heated to 85°C and stirred for 16 h. The obtained solution was evaporated, diluted with NaHCO3solution (5 mL) and EtOAc (30 mL) ,washed with saturated aq. NaHCO3, and brine, dried over Na2SO4, and the solvent was evaporated to yield ethyl 2-(1H-pyrazol-3-yl)acetate (900.0 mg, 5.84 mmol, 94.5% yield). ethyl 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate A mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (100.0 mg, 649.04 µmol), 2-chloro-5-iodo-1,3- thiazole (206.18 mg, 842.03 µmol), tripotassium phosphate (411.65 mg, 1.94 mmol), (1S,2S)- N1,N2-dimethylcyclohexane-1,2-diamine (46.04 mg, 323.86 µmol) and copper iodide (24.59 mg, 129.54 µmol) in degassed anhydrous 1,4-dioxane (6 ml) was heated under argon at 110°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure and purified by HPLC to afford ethyl 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H- pyrazol-3-yl]acetate (73.0 mg, 268.66 µmol, 41.5% yield). 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid To a solution of ethyl 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate (70.0 mg, 257.62 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (13.0 mg, 309.27 µmol) was added at 0°C. The mixture was stirred overnight and then the THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (50.0 mg, 205.2 µmol, 79.6% yield). 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide To a mixture of 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (50.0 mg, 205.77 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (86.06 mg, 226.43 µmol) in DMF (1 mL) 3-cyclopropyl-1H- pyrazol-5-amine (25.34 mg, 205.84 µmol) was added, and the mixture was stirred overnight at 65°C. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to afford 2-[1-(2-chloro-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide, Compound 4, (6.0 mg, 17.2 µmol, 8.4% yield). 1H NMR (CD3OD, 500 MHz) δ (ppm): 0.68 (m, 2H), 0.92 (m, 2H), 1.85 (m, 1H), 3.72 (s, 2H), 6.15 (br s, 1H), 6.50 (d, 1H), 7.72 (s, 1H), 8.13 (d, 1H). LCMS [Method Y] Calculated: 348.06. Found [M+H]+: 349.0; Rt = 0.894 min. Synthesis of Compound 5 ethyl 2-[1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate A mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (300.0 mg, 1.95 mmol), 4-bromo-2-methyl- 1,3-thiazole (413.12 mg, 2.34 mmol), copper iodide (18.47 mg, 97.29 µmol), (1S,2S)-N1,N2- dimethylcyclohexane-1,2-diamine (55.32 mg, 389.17 µmol) and dipotassium carbonate (536.71 mg, 3.89 mmol) in degassed anhydrous 1,4-dioxane (1.5 ml) was heated under argon at 100°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure and purified by HPLC to afford ethyl 2-[1-(2-methyl- 1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate (2-[1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid To a solution of ethyl 2-[1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate (200.0 mg, 795.85 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (36.86 mg, 877.04 µmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2- [1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 671.89 µmol, 84.3% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3- yl]acetamide To a mixture of 2-[1-(2-methyl-1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 672.52 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (281.37 mg, 740.27 µmol) in DMF (1.5 mL) 3-cyclopropyl-1H- pyrazol-5-amine (82.83 mg, 672.98 µmol) was added, and the mixture was stirred overnight at room temperature. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(2-methyl-1,3-thiazol- 4-yl)-1H-pyrazol-3-yl]acetamide, Compound 5, (26.8 mg, 81.61 µmol, 12.1% yield). LCMS [Method Y] Calculated: 328.12. Found [M+H]+: 329.2; Rt = 1.035 min. Synthesis of Compound 6 ethyl 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate A mixture of 4-chloro-2-iodo-1,3-thiazole (262.68 mg, 1.07 mmol), ethyl 2-(1H-pyrazol-3- yl)acetate (150.0 mg, 973.56 µmol), copper iodide (9.26 mg, 48.76 µmol), dipotassium carbonate (269.0 mg, 1.95 mmol) and (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (27.73 mg, 195.05 µmol) in degassed anhydrous 1,4-dioxane (3.5 ml) was heated under argon at 110°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure and purified by HPLC to afford ethyl 2-[1-(4-chloro-1,3- thiazol-2-yl)-1H-pyrazol-3-yl]acetate (44.0 mg, 161.93 µmol, 16.6% yield). 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (40.0 mg, 155.22 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (7.82 mg, 186.15 µmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2- [1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (35.0 mg, 143.64 µmol, 92.6% yield). 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide To a mixture of 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (35.0 mg, 143.64 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (60.05 mg, 157.99 µmol) in DMF (1 mL) 3-cyclopropyl-1H- pyrazol-5-amine (17.68 mg, 143.63 µmol) was added, and the mixture was stirred overnight at room temperature. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide 2-[1-(4-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]-N-(5- cyclopropyl-1H-pyrazol-3-yl)acetamide, Compound 6, (2.9 mg, 8.31 µmol, 5.8% yield). LCMS [Method Y] Calculated: 348.06. Found [M+H]+: 349.2; Rt = 0.967 min. Synthesis of Compound 7 ethyl 2-[1-(4-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate A mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (150.0 mg, 973.56 µmol), 2-iodo-4-methyl-1,3- thiazole (263.12 mg, 1.17 mmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (27.72 mg, 194.98 µmol), dipotassium carbonate (268.9 mg, 1.95 mmol) and copper iodide (9.25 mg, 48.75 µmol) in degassed anhydrous 1,4-dioxane (2 ml) was heated under argon at 110°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure and purified by HPLC to afford ethyl 2-[1-(4-methyl-1,3-thiazol-2-yl)-1H- pyrazol-3-yl]acetate (36.0 mg, 143.25 µmol, 14.7% yield). 2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetic acid To a solution of ethyl 2-[1-(4-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (36.0 mg, 143.25 µmol) in THF (2 ml) / H2O (0.5 ml) mixture lithium hydroxide hydrate (6.63 mg, 157.67 µmol) was added at 0°C. The mixture was stirred overnight, and then THF was distilled off. The remaining aqueous phase was washed with MTBE (1 x 2 mL), and concentrated to afford 2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetic acid as lithium salt (27.0 mg, 117.81 µmol, 84.4% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(4-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3- yl]acetamide To a mixture of 2-[1-(4-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (27.0 mg, 121.05 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (50.67 mg, 133.32 µmol) in DMF (1 mL) 3-cyclopropyl-1H- pyrazol-5-amine (14.92 mg, 121.2 µmol) was added, and the mixture was stirred overnight at 65°C . The mixture was purified by HPLC (30-30-60% 0-1-6 min H2O / MeOH / 0.1%NH4OH, flow: 30 ml / min (loading pump 4 ml / min MeOH); column: XBridge BEH C185 um 130 A) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(4-methyl-1,3- thiazol-2-yl)-1H-pyrazol-3-yl]acetamide, Compound 7, (5.7 mg, 17.36 µmol, 14.3% yield). LCMS [Method Y] Calculated: 328.12. Found [M+H]+: 329.0; Rt = 0.935 min. Synthesis of Compound 8 and Compound 9

[0033] Ethyl 2-(1-(3-bromophenyl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (3 g, 19.459 mmol) and 1,3- dibromobenzene (4.59 g, 19.459 mmol) in DMSO (20 mL) were added K2CO3(5.38 g, 38.918 mmol) and CuI (741.20 mg, 3.892 mmol) in portions at room temperature. The reaction was stirred for 4 h at 120°C under a nitrogen atmosphere. The mixture was diluted with water (1.5 L) and extracted with EtOAc (3 x 400 mL). The combined organic extracts were washed with brine (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(3-bromophenyl)pyrazol-3- yl]acetate (910 mg, 15% yield) as a colourless oil. LCMS Retention time (Method Q) 0.910 min; m / z 309 (M+H) Ethyl 2-(1-(3-bromophenyl)-1H-pyrazol-3-yl)propanoate A solution of ethyl 2-[1-(3-bromophenyl)pyrazol-3-yl]acetate (910 mg, 2.943 mmol) in THF (15 mL) was treated with NaH (117 mg, 4.905 mmol) for 30 min at 0°C under a nitrogen atmosphere followed by the addition of MeI (384 mg, 2.705 mmol) dropwise at 0°C. The reaction was stirred for 2 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (300 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1- (3-bromophenyl)pyrazol-3-yl]propanoate (500 mg, 53% yield) as a colourless oil. LCMS Retention time (Method Q) 0.870 min; m / z 323 (M+H) 2-(1-(3-bromophenyl)-1H-pyrazol-3-yl)propanoic acid A mixture of ethyl 2-[1-(3-bromophenyl)pyrazol-3-yl]propanoate (500 mg, 1.547 mmol) and NaOH (1.20 g, 29.996 mmol) in H2O (10 mL) and THF (5 mL) was stirred for 3 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and acidified to pH 2 with HCl (aq.). The mixture was extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (1:1) to afford 2-[1-(3-bromophenyl)pyrazol-3-yl]propanoic acid (400 mg, 88% yield) as a white solid. LCMS Retention time (Method Q) 0.683 min; m / z 295 (M+H) Tert-butyl 3-(2-(1-(3-bromophenyl)-1H-pyrazol-3-yl)propanamido)-5-cyclopropyl-1H- pyrazole-1-carboxylate To a stirred mixture of 2-[1-(3-bromophenyl)pyrazol-3-yl]propanoic acid (370 mg, 1.254 mmol) and T3P (598.34 mg, 1.881 mmol) in DCM (10 mL) were added TEA (507.45 mg, 5.016 mmol) and tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate (279.91 mg, 1.254 mmol) in portions at room temperature. The reaction was stirred for 3 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (500 mL) and extracted with DCM (3 x 170 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (4:1) to afford tert-butyl 3-{2-[1-(3-bromophenyl)pyrazol-3-yl]propanamido}-5- cyclopropylpyrazole-1-carboxylate (360 mg, 57% yield) as a yellow oil. LCMS Retention time (Method Q) 1.317 min; m / z 500 (M+H) Tert-butyl 3-(2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)propanamido)-5-cyclopropyl-1H- pyrazole-1-carboxylate To a stirred mixture of tert-butyl 3-{2-[1-(3-bromophenyl)pyrazol-3-yl]propanamido}-5- cyclopropylpyrazole-1-carboxylate (300 mg, 0.600 mmol) and Zn(CN)2(84.48 mg, 0.720 mmol) in DMF (5 mL) were added Pd2(dba)3(54.90 mg, 0.060 mmol) and dppf (66.23 mg, 0.120 mmol) in portions at room temperature. The reaction was stirred overnight at 120°C under a nitrogen atmosphere. The mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (3:1) to afford tert-butyl 3-{2-[1-(3-cyanophenyl)pyrazol-3-yl]propanamido}-5- cyclopropylpyrazole-1-carboxylate (160 mg, 60% yield) as a light yellow oil. LCMS Retention time (Method Q) 0.930 min; m / z 447 (M+H) 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide A solution of tert-butyl 3-{2-[1-(3-cyanophenyl)pyrazol-3-yl]propanamido}-5- cyclopropylpyrazole-1-carboxylate (150 mg, 0.336 mmol) in 4 M HCl in 1,4-dioxane (10 mL, 329.128 mmol) was stirred for 30 min at room temperature. The mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 40 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by reversed-phase flash chromatography (Mobile phase: MeCN in water [containing 10 mmol / L NH4HCO3); Gradient: 10% to 50% MeCN] to afford 2-[1-(3-cyanophenyl)pyrazol-3-yl]-N-(5-cyclopropyl-1H- pyrazol-3-yl)propanamide (60 mg, 52% yield) as a white solid. LCMS Retention time (Method Q) 0.623 min; m / z 347 (M+H) 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide Enantiomer 1 and Enantiomer 2 Chiral separation of 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl) propanamide (60 mg) (Column: CHIRAL ART Cellulose-SZ, 3*25 cm, 5 μm; Mobile Phase A: Hexane [containing 0.1% 2 M NH3 in MeOH], Mobile Phase B: EtOH; Flow rate: 40 mL / min; Gradient: isocratic 30% B) afforded: • First eluting isomer / Enantiomer 1, Compound 9 (14.6 mg, 24% yield). LCMS Retention time (Method Q) 1.237 min; m / z 347 (M+H). • Second eluting isomer / Enantiomer 2, Compound 8 (13.4 mg, 22% yield) LCMS Retention time (Method Q) 1.238 min; m / z 347 (M+H) Synthesis of Compound 10 ethyl 2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetate Ethyl 2-(1H-pyrazol-3-yl)acetate (1.0 g, 6.49 mmol), 2-bromopyridine (1.02 g, 6.49 mmol, 610.0 µl, 1.0 equiv.),1,10-phenanthroline (233.76 mg, 1.3 mmol) and cesium carbonate (4.23 g, 12.98 mmol) were added to DMF (30 mL) under Argon atmosphere and then copper bromide (552.42 mg, 3.89 mmol) was added. The reaction mixture was heated to 100°C for 16 h. After cooling to room temperature, the mixture was diluted with water (30 mL) and was extracted with EtOAc (2x70 mL). The combined organic layers were separated, washed with NaHCO3, dried with Na2SO4and concentrated in vacuo to give ethyl 2-[1-(pyridin-2- yl)-1H-pyrazol-3-yl]acetate (1g 90% by LCMS). 2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetic acid To a solution of ethyl 2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetate (1.3 g, 5.62 mmol) in THF / H2O (50 mL / 10 mL) were added sodium hydroxide (337.15 mg, 8.43 mmol) . The mixture was stirred at room temperature overnight. After the completion of the reaction solvents were removed in vacuo and HCl (1M aq. solution) was added until pH 4-5. Then the solution was concentrated in vacuo and to the formed precipitate CH3CN (50 mL) was added, precipitate was filtered off and the solution was evaporated to obtain 2-[1-(pyridin- 2-yl)-1H-pyrazol-3-yl]acetic acid (1.0 g, 76.87% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetamide 2-[1-(Pyridin-2-yl)-1H-pyrazol-3-yl]acetic acid (300.0 mg, 1.48 mmol) was dissolved in DMF (5 mL) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (843.18 mg, 2.22 mmol) and N-Ethyl-N-(propan-2-yl)propan-2-amine (477.51 mg, 3.7 mmol, 640.0 µl) were added to the resulting solution. After stirring for 30 min 3-cyclopropyl-1H-pyrazol-5-amine (182.02 mg, 1.48 mmol) was added. The resulting mixture was stirred at 65°C for 16 h. After confirmation of completion of the reaction by LCMS, the crude product was subjected to HPLC (0-2-7 min0-10-20% H2O / MeCN / 0.1%NH4OH, flow 30 ml / min (loading pump 4 ml MeCN) column: Chromatorex C18 SMB100-5T 100*19 mm, 5 microM). After HPLC N-(5-cyclopropyl-1H-pyrazol-3-yl)-2- [1-(pyridin-2-yl)-1H-pyrazol-3-yl]acetamide, Compound 10, was obtained. LCMS [Method Y] Calculated: 308.15. Found [M+H]+: 309.4; Rt = 0.957 min. Synthesis of Compound 11 methyl 2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate A mixture of 5-iodo-2-methyl-1,3-thiazole (264.84 mg, 1.18 mmol), methyl 2-(1H-pyrazol-5- yl)acetate (150.0 mg, 1.07 mmol), (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (76.08 mg, 535.24 µmol), tripotassium phosphate (680.32 mg, 3.21 mmol) and copper iodide (40.64 mg, 214.09 µmol) in degassed anhydrous 1,4-dioxane (5 ml) was heated under argon at 105°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 ml) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure to afford methyl 2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate (200.0 mg, 842.89 µmol, 78.7% yield). 2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate (200.0 mg, 842.89 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (44.24 mg, 1.05 mmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2- [1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 671.89 µmol, 79.8% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3- yl]acetamide To a mixture of 2-[1-(2-methyl-1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 671.89 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (281.37 mg, 740.27 µmol) in DMF (1 mL) 3-cyclopropyl-1H- pyrazol-5-amine (82.83 mg, 672.98 µmol) was added, and the mixture was stirred overnight at 65°C. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(2-methyl-1,3-thiazol-5-yl)-1H- pyrazol-3-yl]acetamide, Compound 11 (11.9 mg, 36.24 µmol, 5.4% yield). LCMS [Method Y] Calculated: 328.12. Found [M+H]+: 329.2; Rt = 0.797 min. Synthesis of Compound 12 methyl 2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate A mixture of 5-iodo-1,3-thiazole (248.35 mg, 1.18 mmol), methyl 2-(1H-pyrazol-5-yl)acetate (150.0 mg, 1.07 mmol), copper iodide (40.65 mg, 214.11 µmol), tripotassium phosphate (680.36 mg, 3.21 mmol) and (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (76.09 mg, 535.27 µmol) in degassed anhydrous 1,4-dioxane (5 ml) was heated under argon at 110°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure to afford methyl 2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate (200.0 mg, 895.85 µmol, 83.7% yield). 2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetate (200.0 mg, 895.85 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (46.96 mg, 1.12 mmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 ml), and concentrated to afford 2-[1-(1,3- thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 716.93 µmol, 80.2% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetamide To a mixture of 2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 716.93 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (299.25 mg, 787.3 µmol) in DMF (1 mL) 3-cyclopropyl-1H-pyrazol-5- amine (88.09 mg, 715.73 µmol) was added, and the mixture was stirred overnight at 65°C. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(1,3-thiazol-5-yl)-1H-pyrazol-3- yl]acetamide, Compound 12 (5.0 mg, 15.91 µmol, 2.2% yield). LCMS [method Y] Calculated: 314.1. Found [M+H]+: 315.2; Rt = 0.735 min. Synthesis of Compound 13 ethyl 2-(1H-pyrazol-3-yl)acetate 2-(1H-pyrazol-5-yl)acetic acid hydrochloride (13.0 g, 80.24 mmol) and ethoxyethane; trifluoroborane (1.14 g, 8.02 mmol, 1.01 ml) were refluxed in EtOH (100 mL) for 8 h. After that the solvent was removed under reduced pressure and aqueous solution of NaHCO3(50 mL) was added. The aqueous layer was extracted with MTBE (2x75 mL). The combined organic layers were separated, dried with Na2SO4and concentrated in vacuo to give ethyl 2- (1H-pyrazol-3-yl)acetate (0.7 g, crude). ethyl 2-[1-(1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate Sodium hydride (218.05 mg, 9.09 mmol) was added to the stirred solution of ethyl 2-(1H- pyrazol-3-yl)acetate (699.99 mg, 4.54 mmol) in DMF (10 ml) and then it was stirred at room temperature for 30 min. After that 2-bromo-1,3-thiazole (740.13 mg, 4.54 mmol) was added and the reaction mixture was stirred at 100°C for 48 h. To resulting solution was added water (20 mL) and it was extracted with 2x50 ml of ethyl acetate and the organic layers were combined, dried with Na2SO4and concentrated in vacuo to give crude ethyl 2-[1-(1,3- thiazol-2-yl)-1H-pyrazol-3-yl]acetate (400.0 mg, 42.0% yield). 2-[1-(1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid To a solution of ethyl 2-[1-(1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (100.0 mg, 421.45 µmol) in THF / H2O (50 mL / 10 mL) were added sodium hydroxide (25.29 mg, 632.33 µmol) . The mixture was stirred at room temperature overnight. After the completion of the reaction solvents were removed in vacuo and HCl (1M aq. solution) was added until pH 4-5. Then the solution was concentrated in vacuo and to the formed precipitate CH3CN (50 mL) was added, precipitate was filtered off and the solution was evaporated to obtain 2-[1-(1,3- thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (5.3 mg, 25.33 µmol, 6% yield). LCMS [method Y] Calculated: 314.1. Found [M+H]+: 315.0; Rt = 1.034 min. N-(5-Cyclopropyl-1H-pyrazol-3-yl)-2-[1-(1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetamide 2-[1-(1,3-Thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (101.16 mg, 483.51 µmol) was dissolved in DMF (5 mL) and then 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate (275.67 mg, 725.27 µmol) and ethylbis(propan-2- yl)amine (155.82 mg, 1.21 mmol, 210.0 µl) were added to the resulting solution. After stirring for 30 min 3-cyclopropyl-1H-pyrazol-5-amine (59.51 mg, 483.51 µmol) was added. The resulting mixture was stirred at 65 °C for 16 hours. After confirmation of completion of the reaction by LCMS, the crude product was subjected to HPLC. After HPLC N-(5-cyclopropyl- 1H-pyrazol-3-yl)-2-[1-(1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetamide, Compound 13 (5.3 mg, 6.01% yield) was obtained. LCMS [method Y] Calculated: 314.1. Found [M+H]+: 315.0; Rt = 1.034 min. Synthesis of Compound 14

[0034] ethyl 2-[1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate Sodium hydride (218.14 mg, 9.09 mmol) was added to the stirred solution of ethyl 2-(1H- pyrazol-3-yl)acetate (700.28 mg, 4.55 mmol) in DMF (10 ml) and then it was stirred at room temperature for 30 min. After that 2-bromo-5-chloro-1,3-thiazole (984.27 mg, 5.0 mmol) was added and the reaction mixture was stirred at 100°C for 48 h. To resulting solution was added water (20 ml) and it was extracted with 2x50 ml of ethyl acetate and the organic layers were combined, dried with Na2SO4and concentrated in vacuo to give crude ethyl 2- [1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (0.5 g, crude). 2-[1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid To a solution of ethyl 2-[1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (500.0 mg, 1.84 mmol) in THF / H2O (50 mL / 10 mL) were added sodium hydroxide (110.29 mg, 2.76 mmol) . The mixture was stirred at room temperature overnight. After the completion of the reaction solvents were removed in vacuo and HCl (1M aq. solution) was added until pH 4-5. Then the solution was concentrated in vacuo and to the formed precipitate CH3CN (50 mL) was added, precipitate was filtered off and the solution was evaporated to obtain 2-[1-(5- chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (0.15 g, crude). 2-[1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide 2-[1-(5-Chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (150.0 mg, 615.59 µmol) was dissolved in DMF (5 mL) and then 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate (351.42 mg, 924.57 µmol) and N-Ethyl-N- (propan-2-yl)propan-2-amine (199.02 mg, 1.54 mmol, 270.0 µl, 2.5 equiv.) were added to the resulting solution. After stirring for 30 min 3-cyclopropyl-1H-pyrazol-5-amine (75.86 mg, 616.38 µmol) was added. The resulting mixture was stirred at 65°C for 16 h. After confirmation of completion of the reaction by LCMS, the crude product was subjected to HPLC. After HPLC 2-[1-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide, Compound 14 (7.7 mg, 35.98% yield) was obtained. LCMS [Method Y] Calculated: 348.06. Found [M+H]+: 349.0; Rt = 1.134 min. Synthesis of Compound 15 and Compound 16

[0035] Ethyl 2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (2 g, 12.973 mmol) and K2CO3(3.59 g, 25.946 mmol) in DMSO (10 mL) were added 1,3-difluoro-5-iodobenzene (3.11 g, 12.973 mmol) and CuI (0.49 g, 2.595 mmol) in portions at room temperature. The reaction was stirred overnight at 120°C under a nitrogen atmosphere. The mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(3,5-difluorophenyl)pyrazol- 3-yl]acetate (810 mg, 23% yield) as a white solid. LCMS Retention time (Method Q) 0.954 min; m / z 267 (M+H) Ethyl 2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanoate A solution of ethyl 2-[1-(3,5-difluorophenyl)pyrazol-3-yl]acetate (740 mg, 2.779 mmol) in THF (15 mL) was treated with LDA (2 M in THF) (2.09 mL, 4.168 mmol) for 30 min at −78°C under a nitrogen atmosphere followed by the addition of MeI (394.50 mg, 2.779 mmol) dropwise at −78°C. The mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. The reaction was quenched with water (250 mL) and extracted with EtOAc (3 x 160 mL). The combined organic extracts were washed with brine (3 x 60 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (9:1) to afford ethyl 2-[1-(3,5-difluorophenyl)pyrazol-3-yl]propanoate (520 mg, 67% yield) as a yellow liquid. LCMS Retention time (Method E) 0.857 min; m / z 281 (M+H) 2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanoic acid A mixture of ethyl 2-[1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetate (520 mg, 2.120 mmol) and NaOH (1.2 g, 30.002 mmol) in THF (3 mL) and H2O (10 mL) was stirred overnight at room temperature. The mixture was acidified to pH 2 with HCl (aq.), diluted with water (250 mL) and extracted with EtOAc (3 x 120 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (5:1) to afford [1-(6-methylpyridin-2-yl)pyrazol-3- yl]acetic acid (290 mg, 63% yield) as a yellow solid. LCMS Retention time (Method E) 0.763 min; m / z 253 (M+H) Tert-butyl 3-cyclopropyl-5-(2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamido)- 1H-pyrazole-1-carboxylate To a stirred mixture of 2-[1-(3,5-difluorophenyl)pyrazol-3-yl]propanoic acid (290 mg, 1.150 mmol) and T3P (548.76 mg, 1.725 mmol) in DCM (10 mL) were added TEA (465.40 mg, 4.600 mmol) and tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate (256.72 mg, 1.150 mmol) in portions at room temperature. The reaction was stirred for 3 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 120 mL). The combined organic extracts were washed with brine (3 x 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford tert-butyl 5-cyclopropyl-3-{2-[1-(3,5-difluorophenyl)pyrazol-3- yl]propanamido}pyrazole-1-carboxylate (180 mg, 34% yield) as a yellow solid. LCMS Retention time (Method E) 0.883 min; m / z 458 (M+H) N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide A mixture of tert-butyl 5-cyclopropyl-3-{2-[1-(3,5-difluorophenyl)pyrazol-3- yl]propanamido}pyrazole-1-carboxylate (180 mg, 0.393 mmol) in 4 M HCl in 1,4-dioxane (10 mL) was stirred for 30 min at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (3 x 40 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by Prep-HPLC (Mobile Phase A: Water [10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Gradient: 26% B to 44% B) to afford N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(3,5- difluorophenyl)pyrazol-3-yl]propanamide (65 mg, 46% yield) as a white solid. LCMS Retention time (Method C) 1.120 min; m / z 358 (M+H) N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide Enantiomer 1 and Enantiomer 2 Chiral separation of N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H- pyrazol-3-yl)propanamide (65 mg) (Column: CHIRALPAK IA, 2*25 cm, 5 μm; Mobile Phase A: Hexane [containing 10 mM NH3-MeOH], Mobile Phase B: EtOH; Flow rate: 20 mL / min; Gradient: isocratic 50% B) afforded: • First eluting isomer / Enantiomer 1, Compound 16, (29.6 mg, 46% yield). LCMS Retention time (Method D) 1.577 min; m / z 358 (M+H). • Second eluting isomer / Enantiomer 2, Compound 15, (29 mg, 45% yield) LCMS Retention time (Method D) 1.573 min; m / z 358 (M+H) Ethyl 2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetate To a stirred solution of ethyl 2-(1H-pyrazol-3-yl) acetate (2.6 g, 16.86 mmol) and 2-fluoro-4- methylpyridine (2.06 g, 18.55 mmol) in DMSO (25 mL) were added K2CO3(4.66 g, 33.73 mmol) and CuI (642.37 mg, 3.37 mmol) at room temperature. The mixture was stirred overnight at 120°C under a nitrogen atmosphere. The reaction was quenched with sat. NH4Cl (aq.) at room temperature and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (1:1) to afford ethyl 2-(1-(4- methylpyridin-2-yl)-1H-pyrazol-3-yl) acetate (520 mg, 13% yield) as a yellow oil. LCMS Retention time (Method J) 1.016 min; m / z 246 (M+H) 2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetic acid To a stirred solution of ethyl 2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetate (520 mg, 2.12 mmol) in THF (3 mL) and H2O (3 mL) was added NaOH (169.59 mg, 4.24 mmol) and the reaction stirred overnight at room temperature. The mixture was diluted with water and acidified to pH 2 with HCl (aq.). The mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure affording 2- (1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetic acid (350 mg, 76% yield) as a white solid. LCMS Retention time (Method E) 0.763 min; m / z 218 (M+H) Tert-butyl 3-cyclopropyl-5-(2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetamido)- 1H-pyrazole-1-carboxylate To a solution of 2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetic acid (350 mg, 1.61 mmol) and tert-butyl 5-amino-3-cyclopropyl-1H-pyrazole-1-carboxylate (359.74 mg, 1.61 mmol) in DCM (6 mL) were added DIEA (1.04 g, 8.05 mmol) and T3P (4.10 g, 12.88 mmol) at room temperature. The mixture was stirred overnight at room temperature under a nitrogen atmosphere. The reaction was quenched with water and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (7:1) to afford tert-butyl 3-cyclopropyl-5-(2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetamido)-1H- pyrazole-1-carboxylate (150 mg, 22% yield) as a white solid. LCMS Retention time (Method J) 1.220 min; m / z 423 (M+H) N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl) acetamide A solution of tert-butyl 3-cyclopropyl-5-{2-[1-(4-methylpyridin-2-yl) pyrazol-3-yl] acetamido} pyrazole-1-carboxylate (150 mg, 0.35 mmol) in 4 M HCl in 1,4-dioxane (5 mL) was stirred for 20 min at room temperature. The reaction was diluted with water and basified to pH 10 with K2CO3. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by Prep-HPLC (Mobile Phase A: water [containing 10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Gradient: 26% B to 44% B) to afford N-(5-cyclopropyl-1H-pyrazol- 3-yl)-2-[1-(4-methylpyridin-2-yl) pyrazol-3-yl] acetamide, Compound 17 (100 mg, 87% yield) as a white solid. LCMS Retention time (Method K) 1.229 min; m / z 323 (M+H) Synthesis of compound 18 methyl 2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate A mixture of 2-iodo-5-methyl-1,3-thiazole (264.84 mg, 1.18 mmol), methyl 2-(1H-pyrazol-5- yl)acetate (150.0 mg, 1.07 mmol), copper iodide (10.16 mg, 53.52 µmol), dipotassium carbonate (295.26 mg, 2.14 mmol) and (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (30.43 mg, 214.09 µmol) in degassed anhydrous 1,4-dioxane (5 ml) was heated under argon at 105°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure to afford methyl 2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (150.0 mg, 632.17 µmol, 59.1% yield). 2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetate (150.0 mg, 632.17 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (29.2 mg, 694.73 µmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2- [1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (100.0 mg, 447.92 µmol, 70.9% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3- yl]acetamide To a mixture of 2-[1-(5-methyl-1,3-thiazol-2-yl)-1H-pyrazol-3-yl]acetic acid (100.0 mg, 447.92 µmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate (187.16 mg, 492.4 µmol) in DMF (1 mL) 3-cyclopropyl-1H- pyrazol-5-amine (55.09 mg, 447.64 µmol) was added, and the mixture was stirred overnight at 65°C The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(5-methyl-1,3-thiazol-2-yl)-1H- pyrazol-3-yl]acetamide, Compound 18, (3.9 mg, 11.88 µmol, 2.7% yield). LCMS [method Y] Calculated: 328.12. Found [M+H]+: 329.2; Rt = 0.824 min. Synthesis of Compound 19 methyl 2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate A mixture of 4-iodo-1,3-thiazole (248.35 mg, 1.18 mmol), methyl 2-(1H-pyrazol-5-yl)acetate (150.0 mg, 1.07 mmol), copper iodide (10.16 mg, 53.53 µmol), potassium carbonate (295.28 mg, 2.14 mmol) and (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (30.43 mg, 214.11 µmol) in degassed anhydrous 1,4-dioxane (1.5 ml) was heated under argon at 100°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 mL) washed with water (3 x 2 mL), dried over Na2SO4and evaporated under reduced pressure to afford methyl 2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate (120.0 mg, 537.51 µmol, 50.2% yield). 2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetate (120.0 mg, 537.51 µmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (24.75 mg, 588.84 µmol) was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 mL), and concentrated to afford 2-[1-(1,3- thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid (100.0 mg, 477.95 µmol, 89.3% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetamide To a mixture of 2-[1-(1,3-thiazol-4-yl)-1H-pyrazol-3-yl]acetic acid (100.0 mg, 477.95 µmol) and 3-cyclopropyl-1H-pyrazol-5-amine (58.73 mg, 477.15 µmol) in DMF (1 mL) 1- [Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (199.5 mg, 524.87 µmol) was added, and the mixture was stirred overnight at room temperature. The mixture was purified by HPLC (20-50% 0-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(1,3- thiazol-4-yl)-1H-pyrazol-3-yl]acetamide, Compound 19 (25.0 mg, 79.53 µmol, 16.7% yield). LCMS [Method Y] Calculated: 314.1. Found [M+H]+: 315.1; Rt = 1.011 min. Synthesis of Compound 20 and Compound 21

[0036] [1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]methanol To a stirred solution of 1-(3-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxylic acid (8.1 g, 33.75 mmol) in THF (100 mL) was added Lithium aluminium hydride (1.72 g, 50.63 mmol) at 0°C and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was cooled to 0°C and quenched with saturated NaOH solution and filtered through ceolite. The residue was washed with ethyl acetate (100 mL) and the filtrate was dried over anhydrous Na2SO4and concentrated under reduced pressure to afford [1-(3- chloro-4-fluorophenyl)-1H-pyrazol-3-yl]methanol (7.0 g, 91.76% yield) as a yellow solid. The compound was used for the next step without purification. 1-(3-chloro-4-fluorophenyl)-3-(chloromethyl)-1H-pyrazole [1-(3-Chloro-4-fluorophenyl)-1H-pyrazol-3-yl]methanol (7.0 g, 30.97 mmol) in dichloromethane (50 mL) was treated with thionyl chloride (4.38 g, 37.16 mmol, 2.67 ml) and the mixture stirred at room temperature for 12 h. The resulting solution was evaporated to afford 1-(3-chloro-4-fluorophenyl)-3-(chloromethyl)-1H-pyrazole (7.5 g, crude). 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetonitrile To a solution of 1-(3-chloro-4-fluorophenyl)-3-(chloromethyl)-1H-pyrazole (7.5 g, 30.74 mmol) in DMSO (50 mL) was added sodium cyanide (3.01 g, 61.47 mmol) at 25°C. After stirring at 25°C for 12 h, the mixture was treated with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetonitrile (7.0 g, crude). 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetic acid To a suspension of 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetonitrile (7.0 g, 29.78 mmol) in EtOH / H2O (20 mL / 10 mL) was added sodium hydroxide (2.98 g, 74.46 mmol). The mixture was refluxed for 4 h. After the completion of the reaction, it was concentrated under reduced pressure to obtain 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetic acid (7.0 g, crude), which was used at the next step directly without further purification. methyl 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetate 2-[1-(3-Chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetic acid (7.0 g, 27.56 mmol) and ethoxyethane; trifluoroborane (391.54 mg, 2.76 mmol, 350.0 µl) were refluxed in MeOH (100 mL) for 8 h. The solvent was then removed under reduced pressure and aqueous solution of NaHCO3(50 mL) was added. The aqueous layer was extracted with methyl tert-butyl ether (2 x 75 mL). The combined organic layers were separated, dried with Na2SO4and concentrated in vacuo to give methyl 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3- yl]acetate (5.1 g, 69.05% yield). methyl 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoate In a three-necked flask equipped with a tube for introducing an inert gas and a low- temperature thermometer was placed a solution of bis(propan-2-yl)amine (2.31 g, 22.83 mmol, 3.23 ml) in anhydrous THF (25 mL) and the solution was cooled to −78°C under argon. N-butyl lithium (1.52 g, 23.78 mmol, 10.34 ml) was added slowly over 10 minutes. The mixture was stirred for 30 min at 0°C. It was then cooled to −20°C and methyl 2-[1- (3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]acetate (5.1 g, 19.03 mmol) in THF (25 mL) was added followed by iodomethane (3.24 g, 22.83 mmol, 1.42 ml). The reaction mixture was stirred at room temperature overnight under argon. The solvent was removed under reduced pressure and aqueous solution of NaHCO3(20 mL) was added. The aqueous layer was extracted with ethyl acetate (2x50 mL) and the combined organic layers were separated, dried with Na2SO4and concentrated in vacuo. After purification with flash chromatography methyl 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoate (2.0 g, 37.26% yield) was obtained. 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoic acid To a suspension of methyl 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoate (2.0 g, 7.09 mmol) in THF / H2O (20 mL / 5 mL) were added sodium hydroxide (425.35 mg, 10.64 mmol). The mixture was stirred at room temperature overnight. The reaction solvents were removed in vacuo and HCl was added. The formed precipitate was filtered and dried to obtain 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoic acid (0.85 g, 44.29% yield), which was used at the next step directly without further purification. 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide 2-[1-(3-Chloro-4-fluorophenyl)-1H-pyrazol-3-yl]propanoic acid (420.0 mg, 1.57 mmol) was dissolved in DMF (5 mL) and then 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate (893.77 mg, 2.35 mmol) and ethylbis(propan-2- yl)amine (506.16 mg, 3.92 mmol, 680.0 µl) were added. After stirring for 30 min 3- cyclopropyl-1H-pyrazol-5-amine (192.94 mg, 1.57 mmol) was added. The resulting mixture was stirred at 60°C for 16 h. After confirmation of completion of the reaction by LCMS, the crude product was subjected to HPLC to afford 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol- 3-yl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide (38.8 mg, 103.8 µmol, 6.6% yield). 2-[1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide Enantiomer 1 and Enantiomer 2 2-[1-(3-Chloro-4-fluorophenyl)-1H-pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide (38.8 mg, 103.8 µmol) was subjected to chiral HPLC using the following conditions Column: CHIRALPAK IA (250x20 mm, 5 mkm)--IA00CJ-XL001—III, Mobile Phase: 100% MeOH, Flow Rate: 14 mL / min. This afforded: • First eluting enantiomer / enantiomer, Compound 20 (111.34 mg, 29.22% yield), LCMS [method Y] Calculated: 374.13. Found [M+H]+: 374.0; Rt = 3.069 min and • Second eluting enantiomer / enantiomer 2, Compound 21, (12.7 mg, 32.73% yield) LCMS [method Y] Calculated: 374.13. Found [M+H]+: 374.0; Rt = 3.068 min. Synthesis of Compound 22 Ethyl 2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1 g, 6.486 mmol) and K2CO3(1.79 g, 12.972 mmol) in DMSO (6 mL) was added 2-fluoro-6-methylpyridine (720.76 mg, 6.486 mmol) dropwise at room temperature. The mixture was stirred overnight at 120°C under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetate (400 mg, 25% yield) as a yellow oil. LCMS Retention time (Method E) 0.803 min; m / z 246 (M+H) 2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetic acid A mixture of ethyl 2-[1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetate (450 mg, 1.835 mmol) and NaOH (600 mg, 15.001 mmol) in THF (5 mL) and H2O (5 mL) was stirred overnight at room temperature under a nitrogen atmosphere. The mixture was diluted with water (300 mL) and acidified to pH 2 with HCl (aq.). The mixture was extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (1:1) to afford [1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetic acid (360 mg, 90% yield) as a light yellow solid. LCMS Retention time (Method Q) 0.595 min; m / z 218 (M+H) Tert-butyl 3-cyclopropyl-5-(2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamido)- 1H-pyrazole-1-carboxylate To a stirred mixture of [1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetic acid (310 mg, 1.427 mmol) and T3P (3.63 g, 11.416 mmol) in DCM (10 mL) were added tert-butyl 3-amino-5- cyclopropylpyrazole-1-carboxylate (318.63 mg, 1.427 mmol) in portions at room temperature. The mixture was stirred for 16 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford tert-butyl 5-cyclopropyl-3-{2-[1-(6-methylpyridin-2-yl)pyrazol-3- yl]acetamido}pyrazole-1-carboxylate (240 mg, 40% yield) as a yellow solid. LCMS Retention time (Method E) 0.910 min; m / z 423 (M+H) N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3- yl)acetamide A mixture of tert-butyl 5-cyclopropyl-3-{2-[1-(6-methylpyridin-2-yl)pyrazol-3- yl]acetamido}pyrazole-1-carboxylate (240 mg, 0.568 mmol) in 4 M HCl in 1,4-dioxane (10 mL) was stirred for 30 min at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (3 x 40 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by Prep-HPLC (Column: Mobile Phase A: Water [containing 10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Gradient: 17% B to 36% B) to afford N-(5-cyclopropyl-1H-pyrazol- 3-yl)-2-[1-(6-methylpyridin-2-yl)pyrazol-3-yl]acetamide, Compound 22 (42.6 mg, 23% yield) as a white solid. LCMS Retention time (Method E) 1.255 min; m / z 323 (M+H) Synthesis of Compound 23 and Compound 24

[0037] Ethyl 2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1 g, 6.486 mmol) and 1,2-difluoro- 4-iodobenzene (1.56 g, 6.486 mmol) in DMSO (7 mL) were added K2CO3(1.79 g, 12.972 mmol) and CuI (0.25 g, 1.297 mmol) in portions at room temperature. The mixture was stirred for 3 h at 120°C under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (3 x 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(3,4-difluorophenyl)pyrazol- 3-yl]acetate (610 mg, 35% yield) as a colourless liquid. LCMS Retention time (Method E) 1.254 min; m / z 267 (M+H) Ethyl 2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanoate A solution of ethyl 2-[1-(3,4-difluorophenyl)pyrazol-3-yl]acetate (610 mg, 2.291 mmol) in THF (18 mL) was treated with LDA (2 M in THF) (1.72 mL, 3.436 mmol) for 30 min at −78°C under a nitrogen atmosphere followed by the addition of MeI (325.20 mg, 2.291 mmol) dropwise at −78°C. The mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was quenched with water (250 mL) and extracted with EtOAc (3 x 130 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(3,4-difluorophenyl)pyrazol-3-yl]propanoate (590 mg, 92% yield) as a yellow liquid. LCMS Retention time (Method Q) 1.078 min; m / z 281 (M+H) 2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanoic acid A mixture of ethyl 2-[1-(3,4-difluorophenyl)pyrazol-3-yl]propanoate (590 mg, 2.105 mmol) and NaOH (1.8 g, 45.003 mmol) in H2O (15 mL) and THF (3 mL) was stirred overnight at room temperature. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to afford 2-[1-(3,4-difluorophenyl)pyrazol-3-yl]propanoic acid (310 mg, 58% yield) as a white oil. LCMS Retention time (Method Q) 0.889 min; m / z 253 (M+H) Tert-butyl 3-cyclopropyl-5-(2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamido)- 1H-pyrazole-1-carboxylate To a stirred mixture of 2-[1-(3,4-difluorophenyl)pyrazol-3-yl]propanoic acid (310 mg, 1.229 mmol) and HATU (701.01 mg, 1.844 mmol) in DMF (5 mL) were added triethylamine (497.50 mg, 4.916 mmol) and tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate (274.42 mg, 1.229 mmol) in portions at room temperature. The mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. The reaction was quenched with water (250 mL) and extracted with EtOAc (3 x 120 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford tert-butyl 5-cyclopropyl-3-{2-[1-(3,4- difluorophenyl)pyrazol-3-yl]propanamido}pyrazole-1-carboxylate (120 mg, 21% yield) as a colourless liquid. LCMS Retention time (Method E) 0.830 min; m / z 458 (M+H) N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide A mixture of tert-butyl 5-cyclopropyl-3-{2-[1-(3,4-difluorophenyl)pyrazol-3- yl]propanamido}pyrazole-1-carboxylate (120 mg, 0.262 mmol) in 4 M HCl in 1,4-dioxane (10 mL) was stirred for 30 min at room temperature. The mixture was concentrated under reduced pressure. The crude product (100 mg) was purified by Prep-HPLC (Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: MeCN; Gradient: 20% B to 36% B) to afford N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide (20 mg, 21% yield) as a white solid. LCMS Retention time (Method Q) 0.847 min; m / z 358 (M+H) N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide Enantiomer 1 and Enantiomer 2 Chiral separation of N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H- pyrazol-3-yl)propanamide (20 mg) (CHIRAL ART Cellulose-SZ, 2.0*25 cm, 5 μm; Mobile Phase A: Hexane [containing 10 mM NH3-MeOH], Mobile Phase B: IPA; Flow rate: 20 mL / min; Gradient: isocratic 20% B) afforded: • First eluting isomer / Enantiomer 1, Compound 24 (6 mg, 30% yield). LCMS Retention time (Method Q) 1.470 min; m / z 358 (M+H). • Second eluting isomer / Enantiomer 2, Compound 23 (9 mg, 45% yield) LCMS Retention time (Method Q) 1.473 min; m / z 358 (M+H) Synthesis of Compound 25 ethyl 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1 g, 6.486 mmol) and 2-chloro-6- fluoropyridine (853.15 mg, 6.486 mmol) in DMSO (5 mL) were added K2CO3(1.79 g, 12.972 mmol) in portions at room temperature. The mixture was stirred for 4 h at 120°C under a nitrogen atmosphere. The mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(6-chloropyridin-2-yl)pyrazol-3-yl]acetate (1 g, 58% yield) as a yellow solid. LCMS Retention time (Method E) 1.214 min; m / z 266 (M+H) 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetic acid A mixture of ethyl 2-[1-(6-chloropyridin-2-yl)pyrazol-3-yl]acetate (900 mg, 3.387 mmol) and NaOH (1.54 g, 38.578 mmol) in THF (5 mL) and H2O (10 mL) was stirred for 2 h at room temperature. The mixture was concentrated under reduced pressure and diluted with water (250 mL). The mixture was extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (1:1) to afford [1-(6-chloropyridin-2- yl)pyrazol-3-yl]acetic acid (750 mg, 93% yield) as a yellow solid. LCMS Retention time (Method E) 0.947 min; m / z 238 (M+H) tert-butyl 3-(2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetamido)-5-cyclopropyl-1H- pyrazole-1-carboxylate To a stirred mixture of [1-(6-chloropyridin-2-yl)pyrazol-3-yl]acetic acid (380 mg, 1.599 mmol) and T3P (4.07 g, 12.792 mmol) in DCM (10 mL) was added tert-butyl 3-amino-5- cyclopropylpyrazole-1-carboxylate (357.03 mg, 1.599 mmol) in portions at room temperature. The mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (300 mL) and extracted with EtOAc (3 x 160 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (7:1) to afford tert-butyl 3-(2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetamido)-5-cyclopropyl- 1H-pyrazole-1-carboxylate (150 mg, 21% yield) as a white solid. LCMS Retention time (Method E) 1.374 min; m / z 443 (M+H) 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide A mixture of tert-butyl 3-(2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetamido)-5- cyclopropyl-1H-pyrazole-1-carboxylate (150 mg, 0.339 mmol) in 4 M HCl in 1,4-dioxane (12 mL) was stirred for 30 min at room temperature under a nitrogen atmosphere. The mixture was concentrated under reduced pressure and the residue purified by Prep-HPLC (Column: Mobile Phase A: Water [containing 10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Gradient: 23% B to 41% B) to afford 2-[1-(6-chloropyridin-2-yl)pyrazol-3-yl]-N-(5-cyclopropyl-1H- pyrazol-3-yl)acetamide, Compound 25 (24 mg, 21% yield) as a white solid. LCMS Retention time (Method E) 1.382 min; m / z 343 (M+H) Synthesis of Compound 26 Ethyl 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetate To a stirred mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1 g, 6.486 mmol) and K2CO3(1.79 g, 12.972 mmol) in DMSO (5 mL) were added 4-chloro-2-fluoropyridine (853.15 mg, 6.486 mmol) dropwise at room temperature. The mixture was stirred for 3 h at 120°C under a nitrogen atmosphere. The mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (8:1) to afford ethyl 2-[1-(4-chloropyridin-2-yl)pyrazol-3-yl]acetate (1.1 g, 64% yield) as a colourless liquid. LCMS Retention time (Method E) 1.214 min; m / z 266 (M+H) 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetic acid A mixture of ethyl 2-[1-(4-chloropyridin-2-yl)pyrazol-3-yl]acetate (1.1 g, 4.140 mmol) and NaOH (1.2 g, 30.002 mmol) in H2O (10 mg) and THF (2 mL) was stirred for 2 h at room temperature. The mixture was concentrated under reduced pressure and diluted with water (250 mL). The mixture was extracted with EtOAc (3 x 170 mg). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (1:1) to afford [1-(4-chloropyridin-2- yl)pyrazol-3-yl]acetic acid (900 mg, 92% yield) as a white solid. LCMS Retention time (Method E) 0.710 min; m / z 238 (M+H) Tert-butyl 3-(2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)acetamido)-5-cyclopropyl-1H- pyrazole-1-carboxylate To a stirred mixture of [1-(4-chloropyridin-2-yl)pyrazol-3-yl]acetic acid (800 mg, 3.366 mmol) and T3P (8.57 g, 26.928 mmol) in DCM (1 mL) were added tert-butyl 3-amino-5- cyclopropylpyrazole-1-carboxylate (751.64 mg, 3.366 mmol) in portions at room temperature. The mixture was stirred for 3 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 60 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (5:1) to afford tert-butyl 3-{2-[1-(4-chloropyridin-2-yl)pyrazol-3-yl]acetamido}-5- cyclopropylpyrazole-1-carboxylate (300 mg, 20% yield) as a yellow solid. LCMS Retention time (Method E) 0.910 min; m / z 443 (M+H) 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide A mixture of tert-butyl 3-{2-[1-(4-chloropyridin-2-yl)pyrazol-3-yl]acetamido}-5- cyclopropylpyrazole-1-carboxylate (300 mg, 0.677 mmol) in 4 M HCl in 1,4-dioxane (15 mL) was stirred for 30 min at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by reversed-phase flash chromatography (Column: Mobile Phase A: Water [containing 10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Gradient:10% to 50%) to afford 2-[1-(4- chloropyridin-2-yl)pyrazol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, Compound 26 (52 mg, 22% yield) as a white solid. LCMS Retention time (Method E) 1.340 min; m / z 343 (M+H) Synthesis of Compound 27 and Compound 28

[0038] 3-Bromo-1-(3-chlorophenyl)-1H-pyrazole To a stirred mixture of 3-bromo-1H-pyrazole (7 g, 47.627 mmol) and m- bromochlorobenzene (13.68 g, 71.441 mmol) in DMSO (60 mL) were added K2CO3(13.16 g, 95.254 mmol) and CuI (1.81 g, 9.525 mmol) in portions at room temperature. The mixture was stirred overnight at 120°C under a nitrogen atmosphere. The reaction was quenched by the addition of water (500 mL) at room temperature and extracted with EtOAc (3 x 300 mL). The combined organic extracts were washed with brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (5:1) to afford 3-bromo-1-(3-chlorophenyl)pyrazole (5.03 g, 41% yield) as a white solid. LCMS Retention time (Method Q) 0.869 min; m / z 259 (M+H) Tert-butyl 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)acetate To a stirred mixture of 3-bromo-1-(3-chlorophenyl)pyrazole (5.03 g, 19.532 mmol) and 2- tert-butoxy-2-oxoethylzinc bromide (10.17 g, 39.064 mmol) in THF (50 mL) was added PdCl2(Amphos)2 (1.38 g, 1.953 mmol) in portions at room temperature. The mixture was stirred overnight at 65°C under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 300 mL). The combined organic extracts were washed with brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to afford tert-butyl 2-[1-(3-chlorophenyl)pyrazol- 3-yl]acetate (580 mg, 10% yield) as a colourless liquid. LCMS Retention time (Method Q) 0.847 min; m / z 293 (M+H) Tert-butyl 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanoate A solution of tert-butyl 2-[1-(3-chlorophenyl)pyrazol-3-yl]acetate (580 mg, 1.981 mmol) in THF (10 mL) was treated with NaH (57.05 mg, 2.377 mmol) for 30 min at 0°C under a nitrogen atmosphere followed by the addition of MeI (281.20 mg, 1.981 mmol) dropwise at 0°C. The mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The reaction was quenched with water (250 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (3 x 70 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:1) to afford tert-butyl 2-[1-(3-chlorophenyl)pyrazol-3-yl]propanoate (420 mg, 69% yield) as a yellow liquid. LCMS Retention time (Method Q) 0.885 min; m / z 307 (M+H) 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanoic acid A mixture of tert-butyl 2-[1-(3-chlorophenyl)pyrazol-3-yl]propanoate (420 mg, 1.369 mmol) and TFA (3 mL) in DCM (12 mL) was stirred for 2 h at room temperature under a nitrogen atmosphere. The mixture was concentrated under reduced pressure to afford crude 2-(1-(3- chlorophenyl)-1H-pyrazol-3-yl)propanoic acid (330 mg) as a yellow liquid, which was used in the next step without further purification. LCMS Retention time (Method Q) 0.667 min; m / z 251 (M+H) tert-butyl 5-(2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamido)-3-cyclopropyl-1H- pyrazole-1-carboxylate To a stirred mixture of 2-[1-(3-chlorophenyl)pyrazol-3-yl]propanoic acid (300 mg, 1.197 mmol) and T3P (571.17 mg, 1.796 mmol) in DCM (15 mL) were added triethylamine (484.41 mg, 4.788 mmol) and tert-butyl 3-amino-5-cyclopropylpyrazole-1-carboxylate (293.92 mg, 1.317 mmol) in portions at room temperature. The mixture was stirred for 2 h at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (3 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by silica gel column chromatography eluting with PE / EA (4:1) to afford tert-butyl 5-(2-(1-(3-chlorophenyl)-1H- pyrazol-3-yl)propanamido)-3-cyclopropyl-1H-pyrazole-1-carboxylate (420 mg, 77% yield) as a yellow liquid. LCMS Retention time (Method Q) 0.861 min; m / z 456 (M+H) 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide A mixture of tert-butyl 5-(2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)propanamido)-3- cyclopropyl-1H-pyrazole-1-carboxylate (100 mg, 0.219 mmol) and 4 M HCl in 1,4-dioxane (10 mL) was stirred for 30 min at room temperature under a nitrogen atmosphere. The mixture was diluted with water (250 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with brine (3 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue purified by Prep-HPLC (Mobile Phase A: Water [containing 10 mmol / L NH4HCO3], Mobile Phase B: MeCN; Flow rate: 60 mL / min; Gradient: 30% B to 48% B) to afford 2-(1-(3- chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide (35 mg, 45% yield) as a white solid. LCMS Retention time (Method G) 1.109 min; m / z 356 (M+H) 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide Enantiomer 1 and Enantiomer 2 Chiral separation of 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide (35 mg) (Column: CHIRALPAK IA, 2*25 cm, 5 μm; Mobile Phase A: MtBE [containing 10 mM NH3-MeOH], Mobile Phase B: EtOH; Flow rate: 20 mL / min; Gradient: isocratic 10% B) afforded: • First eluting isomer / Enantiomer 1, Compound 28 (17.9 mg, 51% yield). LCMS Retention time (Method Q) 1.474 min; m / z 356 (M+H) • Second eluting isomer / Enantiomer 2, Compound 27 (11.4 mg, 32% yield). LCMS Retention time (Method Q) 1.470 min; m / z 356 (M+H) 2-[1-(3-methylphenyl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(3-methylphenyl)-1H-pyrazol-3-yl]acetate (0.1 g, 0.43 mmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (20 mg, 0.47 mmol) was added at 0°C. The mixture was stirred overnight and THF was concentrated. The solution was washed with MTBE (3 x 1 ml) and concentrated to afford lithium 2-[1-(3-methylphenyl)-1H- pyrazol-3-yl]acetate (50.0 mg, 0.22 mmol, 51% yield). N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(3-methylphenyl)-1H-pyrazol-3-yl]acetamide To a mixture of 2-[1-(3-methylphenyl)-1H-pyrazol-3-yl]acetic acid (50.0 mg, 231.39 µmol) and 3-cyclopropyl-1H-pyrazol-5-amine (28.47 mg, 231.34 µmol) in DMF (1 mL), 1- [Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (96.7 mg, 254.4 µmol) was added, and the mixture was stirred overnight at room temperature. The mixture was purified by HPLC (25-25-55% 0-1.5-5 min H2O / MeCN, flow: 30 ml / min (loading pump 4 ml / min acetonitrile); column: Chromatorex 18 SMB100-5T 100x19 mm 5 um) to provide N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[1-(3- methylphenyl)-1H-pyrazol-3-yl]acetamide, Compound 29 (11.0 mg, 34.23 µmol, 14.8% yield). LCMS [Method Y] Calculated: 321.18. Found [M+H]+: 322.2; Rt = 1.233 min. Synthesis of Compound 30

[0039] methyl 2-[1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3-yl]acetate A mixture of methyl 2-(1H-pyrazol-5-yl)acetate (100.0 mg, 713.99 µmol), 1-fluoro-4-iodo-2- methylbenzene (185.05 mg, 784.28 µmol), (1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine (20.27 mg, 142.6 µmol), copper iodide (6.77 mg, 35.65 µmol) and potassium carbonate (196.66 mg, 1.43 mmol) in degassed anhydrous toluene (3 ml) was heated under argon at 110°C for 16 h. After cooling to room temperature, the solvent was evaporated, diluted with EtOAc (20 ml) washed with water (3 x 2 ml), dried over Na2SO4and evaporated under reduced pressure to afford methyl 2-[1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3-yl]acetate (120.0 mg, 483.38 µmol, 67.8% yield). 2-[1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3-yl]acetic acid To a solution of methyl 2-[1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3-yl]acetate (0.12 g,0.48 mmol) in THF (3 ml) / H2O (1 ml) mixture lithium hydroxide hydrate (24 mg, 0.58 mmol)was added at 0°C. The mixture was stirred overnight, THF was distilled off, the remaining aqueous phase was washed with MTBE (2 x 2 ml), acidified with NaHSO4and extracted with EtOAc (3 x 5 ml) which was dried over Na2SO4and concentrated to afford 2-[1-(4- fluoro-3-methylphenyl)-1H-pyrazol-3-yl]acetic acid (100.0 mg, 426.94 µmol, 88...

Claims

CLAIMS 1. A compound of formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof:wherein A is a 5-membered heteroaryl group, which comprises one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heteroaryl group is independently unsubstituted or substituted with one or more, same or different substituents RA, provided that at least one substituent RAis present at the heteroaryl group A; wherein RAis halogen, CN, C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl- C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1- C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C4-alkyl B is any one of the following groupswherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RB1is H; RB2is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB3is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB4is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H; X1is N or CRB6; Y1is N or CRB7; Z1is N or CRB8; provided that one, but not more than one of X1, Y1, and Z1is N; RB6is H; RB7is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB8is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB9is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB10is H; RB11is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB12is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB13is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB14is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2;RB15is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; and RB16is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RB17is H, halogen, CN, OH, NH2, NH(RN), N(RN)2, C(=O)OH, C(=O)ORN, OC(=O)RN, C(=O)NH2, C(=O)NH(RN), C(=O)N(RN)2, NHC(=O)RN, N(RN)C(=O)RN, S(O)2OH, S(O)2ORN, S(O)2NH2, S(O)2NH(RN), S(O)2N(RN)2, NHS(O)2RN, N(RN)S(O)2RN, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2- alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, HS-C1-C4-alkyl-, C1-C4- aminoalkyl, -C1-C4-alkyl-NH(RN), -C1-C4-alkyl-N(RN)2; RNis C1-C4-alkyl; and R1is H or C1-C4-alkyl; and wherein the compound is not any one ofor a tautomer thereof.

2. The compound according to claim 1, wherein RB1is H; RB2is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl,C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB3is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB4is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H; RB6is H; RB7is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB8is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB9is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB10is H; RB11is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB12is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB13is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB14is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl,C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB15is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; RB16is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl; and RB17is H, halogen, CN, OH, NH2, NH(CH3), N(CH3)2, C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4- haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C2-alkoxy-C1-C2-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkyl-S-, C1-C4-alkyl-S(O)2-, C1-C4-aminoalkyl, -C1-C4-alkyl-NH(CH3), or C1-C4- dimethylaminoalkyl.

3. The compound according to claim 1 or 2, wherein A is the following heteroaryl groupwherein X2is N or NH; Y2is CH, CRA2, N, NH, or S; Z2is CH, CRA4, N, NH, or S; provided that at least one of Y2and Z2is different from CH, CRA2or CRA4; and wherein the wavy line marks the connection to the remainder of the molecule; and wherein the dashed lines within the 5-membered ring indicate the presence of double bonds, such that an aromatic ring system is formed; and wherein RA2, RA3, and RA4represent the one or more, same or different substituents RAat the heteroaryl group A as defined in claim 1.

4. The compound according to any one of claims 1 to 3, wherein A is any one of the following heteroaryl groups:; wherein the wavy line in each case marks the connection to the remainder of the molecule; andwherein RA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated or partially unsaturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2- alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2- alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl.

5. The compound according to any one of claims 1 to 4, wherein A is any one of the following heteroaryl groups; wherein the wavy line in each case marks the connection to the remainder of the molecule; and wherein RA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl.

6. The compound according to any one of claims 1 to 4, wherein; wherein the wavy line marks the connection to the remainder of the molecule; and whereinRA3is C1-C6-alkyl, C1-C6-haloalkyl, or 3- to 10-membered saturated carbocyclyl, carbocyclyl-C1-C2-alkyl, carbobicyclyl, carbobicyclyl-C1-C2-alkyl, heterocyclyl, heterocyclyl-C1-C2-alkyl, heterobicyclyl, or heterobicyclyl-C1-C2-alkyl, wherein the aforementioned heterocyclic or heterobicyclic rings comprise one or more, same or different heteroatoms selected from O, N, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RY; wherein RYis Cl, F, or C1-C2-alkyl.

7. The compound according to any one of claims 3 to 6, wherein RA3is any one of the following groups CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3,wherein the wavy line in each case marks the connection to the A group.

8. The compound according to any one of claims 3 to 7, wherein RA3is, wherein the wavy line marks the connection to the A group.

9. The compound according to any one of claims 1 to 8, wherein B iswherein the wavy line marks the connection to the remainder of the molecule; and wherein RB1is H; RB2is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB3is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB4is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; and RB5is H; provided that at least one of RB2, RB3, and RB4is different from H.

10. The compound according to any one of claims 1 to 9, whereinwherein the wavy line marks the connection to the remainder of the molecule; and wherein RB7is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB8is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; RB9is H, Cl, F, CN, OH, NH2, CH3, CHF2, CF3, OCH3, CH2OCH3, CH2OH, or CH2NH2; and RB10is H.

11. The compound according to any one of claims 1 to 10, wherein R1is H.

12. The compound according to any one of claims 1 to 10, wherein R1is C1-C4-alkyl.

13. The compound according to claim 12, wherein the compound is a compound of formula (IA).

14. The compound according to claim 12, wherein the compound is a compound of formula (IB)15. The compound according to any one of claims 1 to 10 or 12 to 14, wherein R1is CH3.

16. The compound according to any one of claims 1 to 15, wherein the compound is selected from the group consisting of: N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(2-methylthiazol-4-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylthiazol-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (R)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-cyanophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(pyridin-2-yl)-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(5-chlorothiazol-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,5-difluorophenyl)-1H-pyrazol-3-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide,N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(thiazol-4-yl)-1H-pyrazol-3-yl)acetamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)propanamide, (R)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, (S)-2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(6-methylpyridin-2-yl)-1H-pyrazol-3-yl)acetamide, (R)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, (R)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, (S)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3- yl)propanamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)propanamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(6-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(4-chloropyridin-2-yl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)propanamide, (R)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, (S)-2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)propanamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(m-tolyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide,N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluoro-3-methylphenyl)-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3- yl)acetamide, 2-(1-(3-chloro-4-fluorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5- yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)acetamide, 2-(1-(3-(hydroxymethyl)phenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2- yl)acetamide, 2-(1-(3-fluorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-chlorophenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, 2-(1-(3-methoxyphenyl)-1H-pyrazol-3-yl)-N-(5-(trifluoromethyl)thiazol-2-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropylthiazol-2-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide, and N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)acetamide.

17. A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound according to any one of claims 1 to 16 and optionally a pharmaceutically acceptable carrier, diluent or excipient.

18. A compound according to any one of claims 1 to 16 or a pharmaceutical composition according to claim 17 for use in medicine.

19. A compound according to any one of claims 1 to 16 or a pharmaceutical composition according to claim 17 for use in treating or preventing cancer, a metabolic disorder, a neurologic disorder or an infectious disease, preferably for use in treating or preventing cancer, wherein particularly preferably the cancer is selected from the group consisting of leukemia, particularly acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), and a chronic leukemia including chronic myeloid leukemia; lymphoma, particularly Non-Hodgkin Lymphoma and Hodgkin Lymphoma; head and neck cancer; esophageal cancer; adenoid cystic carcinoma; osteosarcoma; ovarian cancer; Ewing’s sarcoma; lung cancer; neuroblastoma, gastrointestinal cancer, endometrial cancer, cervical cancer, medulloblastoma, prostate cancer, breast cancer, thyroid cancer, meningioma, liver cancer, colorectal cancer, pancreatic cancer, chondrosarcoma, osteosarcoma, and kidney cancer.

Images